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Abstract
Abstract
The multi-subunit alkene monooxygenase was studied by means of electrospray
ionisation mass spectrometry (ESI-MS). The measured relative molecular mass (RMM)
values for the epoxygenase and reductase were in good agreement the predicted RMM
values calculated by means of gene sequencing. Cleavage sites were identified by
means ofESI-MS at the N- and C- terminus of the coupling protein. Cleavage at the C-
terminus inactivated the protein but was shown to be prevented by the addition of a
protease inhibitor, benzamidine.
The ceroid lipofuscinosis protein (CLP) was found to contain a +42.2 Da modification.
Low energy tandem mass spectrometry confirmed 80% of the primary sequence of the
CLP, indicating that the discrepancy in RMM is located on amino acid residues 30-46.
Bovine heart mitochondrial subunit c was extracted as a control and was also found to
contain the +42.2 Da modification. A study of the interaction ofCLP with its diagnostic
inhibitor DCCD was performed. This indicated that the primary product of the reaction
was an acetyl-CLP complex and not the expected CLP-DCCD complex.
The p-subunit of the soluble methane monooxygenase (sMMO) was investigated by
means of ESI-MS to locate and identify a +126.3 Da discrepancy in RMM. A tryptic
digestion of the protein indicated the discrepancy to be located in a small digest peptide
consisting of amino acid residues 141-146. Low energy MSIMS was used to correct the
primary sequence of this peptide. The revised sequence was supported by the close
similarity between the DNA nucleotide sequence for the originally suggested amino
acid residue sequence and the revised sequence.
The binding between a 17 amino acid micro-antibody (Micro-Ab) and two peptides
which represent the V3 region of the gp 120 external glycoprotein of the HIV-l
envelope protein were studied by means ofESI-MS. Itwas found that the interaction
between the Micro-Ab and the two V3 peptides could be maintained and thus observed
directly by ESI-MS. A rapid method of epitope identification was devised whereby the
antigen was pre-digested before incubation with the Micro-Ab. The data identified a
similar series of amino acid residues in both V3 peptides as the epitope with which the
Micro-Ab interacts.
XXVlll
CHAPTER!
INTRODUCTION
Chapter 1.' Introduction
1.1 Introduction to mass spectrometry
Mass spectrometry (MS) is an analytical technique which one can use to determine
accurately the relative molecular mass of an ionised sample. Mass spectrometry offers
both high sensitivity and selectivity and thus finds useful applications in many areas of
research. Furthermore, tandem mass spectrometry (MSIMS) can be used to ascertain
structural information about a sample. This can be useful in identifying compounds in
complex mixtures and determining structures of unknown materials.
There are several different types of mass spectrometer available, each with it's own
advantages and disadvantages. The choice of mass spectrometer is highly dependent
upon the application. The different types of instrument are normally classified by the
mass analyser they employ. All mass spectrometers are composed of four distinct
sections; ionisation source, mass analyser, ion detection and data system as represented
in Figure 1.1.
Ion
Source
M ass
--. Analyser
Ion
Detector
Data
System
Figure 1.1. The four sections of a mass spectrometer.
Chapter 1:Introduction
Although the origins of mass spectrometry can be traced back to the beginning of the
century with the work of J.J. Thomson [1], it was not until the 1940s that the first
commercial instruments were available. These instruments were developed for analysis
of hydrocarbons in the oil industry. At that time the only ionisation source available was
electron impact (El) developed by Nier [2] after its conception by Dempster [3].
El involves bombarding a neutral gaseous sample with a beam of energetic electrons.
The energetic electrons interact with the sample by passing close to it or even through
the molecule to eject an electron from the neutral molecule. Thus two electrons leave
the reaction region, leaving a positively charged molecular ion. At 70 electron volts
(eV) these interactions can leave the molecular ion with a range of internal energies
causing extensive fragmentation to occur. This can be very desirable for gaining
structural information about the sample molecule, although it can result in a low
intensity parent ion peak making relative molecular mass determination difficult. El
proved to be very reproducible and popular and still finds widespread use today.
Chemical ionisation (Cl), developed in 1966 [4], generates ions by means of ion-
molecule reactions between gaseous sample molecules and, in many cases, protonated
reagent gases, such as CHs+. As the technique produces mainly protonated molecular
ions of the type (MH+) and promotes little fragmentation it is deemed to be a milder
ionisation technique than El.
2
Chapter 1.' Introduction
Both El and Cl suffer from a major weakness: they require the sample to be in the gas
phase and thus cannot accommodate large involatile molecules or thermally sensitive
compounds. This restriction means that large polar compounds, such as proteins and
peptides, are usually unsuitable for analysis by El I Cl due to their low volatility and
frequent large size.
Ionisation of thermally labile, involatile molecules was made possible with the
introduction offield ionisation [5] and field desorption [6] (FI I FD). Using these
techniques the analyte is ionised by intense local electric fields. Itwas, however, the
introduction of fast atom bombardment mass spectrometry (FAB-MS) [7] in 1981 that
started what has subsequently become a rapidly expanding area of research: biological
mass spectrometry.
FAB employs a high energy beam of fast atoms to bombard a liquid target surface to
produce continuous desorption of ions which are characteristic of the liquid. When a
sample is dissolved in a solvent oflow volatility, both positive and negative molecular
ions or quasimolecular sample ions are produced. FAB is performed by mixing a
sample solution of approximately 1J..lLwith approximately 1-2 J..lLof matrix and placing
it on a target, which is usually the tip of a direct insertion probe. Upon insertion into the
mass spectrometer, the sample is bombarded with fast atoms.
It was later found that a primary beam of fast ions could utilised instead of atoms, this
3
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technique was termed liquid secondary ion mass spectrometry (LSIMS) [8]. A
development of standard or static FAB was continuous flow FAB (CF-F AB) [9] which
makes use of a flowing carrier solution which continuously refreshes the target surface.
This has the advantage of allowing the sample to be introduced in a liquid form for mass
spectrometric analysis and of significantly reducing the amount of matrix required in the
target mixture.
CF-FAB also facilitates the union of high performance liquid chromatography- mass
spectrometry (HPLC-MS) [10]. In general FAB and LSIMS gives excellent results up
to approximately 2000 mass / charge (mlz), but above this value the abundance of the
molecular ions usually tends to decrease until in the region of 5000-6000 mlz the ions
become difficult or impossible to observe. This means that peptides and digest peptides
of proteins can be analysed, but larger intact proteins are not suited to this method of
ionisation.
Unquestionably the two ionisation techniques which have had the largest impact on
biological mass spectrometry are electrospray ionisation (ESI) and matrix assisted laser
desportion ionisation (MALDI). ESI has been used throughout this work and is
discussed in greater detail in section 2.2.
During MALDI, first described in 1987 [11,12], the sample is mixed with a large molar
excess of matrix and placed on a target, this is in contrast to the earlier technique of
laser desorption (LD) [13] which did not use a matrix. Typically the analyte is
4
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dissolved in a matrix which absorbs strongly at the wavelength of the laser, e.g. 337 nm
for a nitrogen laser. A drop of this solution is then allowed to evaporate slowly on a
target. The target is then placed into the ion source of a suitable, typically time of flight
(TOF) because of the pulsed ion source, mass spectrometer and irradiated with a laser.
Provided the matrix absorbs at the particular wavelength of the laser, energy is
transferred to the matrix and by one of several mechanisms ions are transferred to the
gas phase.
Sample preparation is of particular importance in MALDI-MS ifhigh quality data are
desired. Several different methods have been described for the production ofMALDI
sample targets such as the dried droplet method [11], the thin polycrystalline film [13]
and electro spraying the sample solution onto the target [14]. Ionisation of the sample by
a laser differs from FABILSIMS as the energetic primary beam is made up of photons
which have no significant momentum. MALDI has found widespread use in the study
of proteins and peptides and in conjunction with ESI permits the mass spectrometric
analysis of a large range of biological samples.
The second section of a mass spectrometer is the mass analyser. Its function is to
separate the ions, fanned in the ion source, according to their mlz ratio. At present
there are five types of commonly encountered mass analysers; magnetic sectors,
quadrupole mass filters, time of flight (TOF), quadrupole ion trap (QIT) and fourier-
transform ion cyclotron resonance (FT -ICR) instruments. The two types of mass
5
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analyser used during this work were a quadrupole mass filter and a TOF mass analyser,
hence these are discussed in greater detail in sections 2.3(a) and 2.4(a) respectively.
The three commonly encountered mass analysers not utilised in this work have found
interesting applications in the study of proteins and peptides.
Magnetic sector instruments coupled with FAB and ESI have been used to good effect in
this area of research due to their excellent resolution and mass accuracy capabilities
[15,16,17]. Increasingly however these types of instrument are being superseded by
smaller, simpler types of mass spectrometer for biological mass spectrometric
applications. This is in part because magnetic sector instruments are large, expensive,
complex in operation and pose considerable technical difficulties when coupling
atmospheric pressure ionisation techniques to the large accelerating potentials they
employ within the ion source region. Another important factor in their demise is that
instruments such as MALDI-TOF, ESI- quadrupole, ESI-TOF and QIT are constantly
improving in performance to a point where, although they may not be a match for the
specifications of some sector instruments, they are often able to answer the biological
problem under investigation.
The QIT was first described in 1953 [18], when it was used primarily as a storage device
for spectroscopic analysis. Itwas not until 1984 with the introduction of a new rapid
method of scanning mass spectra [19] that interest in this type of mass analyser started
to occur. The QIT is a small simple instrument, although the theory of ion motion
within the trap itself is very complex. The commercial QIT instruments available tend
6
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to be coupled to ESI [20,21]. In these instruments octapole ion guides are used to
transfer the ions from the atmospheric pressure of the ESI source to the very low
pressures at which the trap is required to operate. Typically a commercial ion trap
instrument currently available has a resolution of approximately 8000 at mlz 2000. The
mass range is also very good with proteins up to 100 kDa being easily investigated.
Because the QIT is an ion storage device, unlike most conventional instruments, it is
particularly suitable for MSN experiments in time rather than space, with the use of
minimum sample[22].
FT-ICR-MS offers the ultimate performance both in terms of resolution and mass
accuracy. First described in the mid 1970s [23] FT-ICR-MS has found most success in
the analysis of'bio-molecules when used in combination with ESI.
FT-ICR-MS can produce ultra-high resolution spectra; for example McLafferty and co-
workers [24] reported a mass resolution in excess of6 x 104 for the 17+charge state of
cytochrome c at 773 mJz. Later this value was increased when the same workers
reported a resolution of2 x 106 for the 10+ charge state of ubi quit in at 857 mlz [25].
Like the QIT the FT-ICR-MS is capable ofMSN. This makes for a very powerful
analytical technique when combined with the ultra high resolution of these instruments
which makes it feasible to assign high charge state fragment ions. When used with ESI
FT-ICR-MS has an extremely high mass range. Smith and co workers have
demonstrated that a molecule, a coliphage T4 DNA, with a molecular weight of 1.1 x
108 can be detected by ESIIFTICR [26].
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The mass accuracy achievable by FTICR is also very high. In 1991 McLafferty reported
a mass accuracy of 1 parts per million (ppm) for isotopically resolved myoglobin [27].
As with all mass spectrometers there are disadvantages with the FTICR instrument;
these include the extremely high cost, complex operation and the limitations imposed by
the extremely low pressures at which the ICR cell operates.
For all types of mass analyser except the FT-ICR instrument, ions are transported
towards a detector system which measures their relative abundance, ion detection is
discussed in detail in sections 2.3 (b) and 2.4 (b). In the FT-ICR instrument, ions are
detected by the absorption of radio frequency (R.F.) power and so, uniquely, they are
not destroyed at the moment of detection. The final section of the mass spectrometer,
the data system, is then used to process the data to produce the mass spectrum.
1.2 Bioloeical Mass Spectrometry
In the last 20 years biological mass spectrometry has emerged as an increasingly
important area of research. This is due, most recently, to the development ofESI and
MADLI which has enabled the ionisation of both peptides and large proteins. Peptides
and proteins consist of a variable number of amino acid residues linked together by
peptide bonds. The difference between peptides and proteins is one of size; peptide
refers to a molecule composed of a small number of amino acid residues, whilst proteins
are much larger. The most important feature of proteins is that their larger size means
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that they posses well defined three-dimensional structures. For example, haemoglobin,
which transports oxygen from the lungs to the rest of the body has a precise shape which
allows oxygen to bind reversibly [28]. In contrast peptides do not possess a well defined
three-dimensional structure.
There are twenty common a-amino acids [29]. They all have the same generalized
structure shown in Figure 1.2, the only difference between them is the nature of the R-
group which specifies the amino acid.
Figure 1.2. Generalised amino acid structure, where R characterises the
amino acid type.
Protein structure can be classified as primary. secondary, tertiary and quaternary [30].
The primary structure describes the order of the amino acid residues of which the protein
9
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is composed, whilst the secondary structure refers to regular features of the protein such
as a-helices and p-sheets. Tertiary structure describes the three-dimensional shape of
the protein and the quaternary structure refers to the arrangement of proteins within
multi-subunit proteins.
1.2 (a) Relative molecular mass determination / primary sequence determination
There are many questions about a protein which can be answered by the accurate
determination of its relative molecule mass (RMM).
Frequently the primary structure of a protein has been deduced from the base sequence
of the gene coding for the protein. The predicted amino acid residue sequence can thus
be imported into a protein data base, from which a predicted RMM value for the protein
can be obtained. The correctness of the sequence can then be checked in the first
instance by comparing the predicted and measured RMM values of the protein [31]. If
the two values agree then this is a good indication that the deduced amino acid residue
sequence is correct.
If the two values disagree it is an indication of an error in the DNA deduced amino acid
residue sequence. Such a mismatch can be caused either by the misidentification of a
nucleotide base, which may change the base triplet to the colon for a different amino
acid residue, or by missing a base (deletion) or by inserting a fictitious base (insertion)
during the interpretation ofthe sequencing gel [32]. In this situation or when greater
mass accuracy is required to differentiate mutations that produce aIDa difference (i.e.
10
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Asp and Asn, Leu/lle and Asn, Glu and GIn), the peptide mapping approach can be
used.
Following this methodology the protein is digested by a highly specific proteolytic
reagent. Trypsin is a common choice, it hydrolyses peptides and proteins on the
carboxyl side of arginine and lysine amino acid residues [33]. These residues occur with
moderate frequency in most proteins, so that trypsin digestion usually provides good
sequence coverage without resulting in too many digest peptides which would hinder
their assignment. If disulfide bonds are present in the protein or peptide to be digested
these typically have to reduced and alkylated prior to digestion; failure to do this often
results in reduced sequence coverage.
The measured digest peptide RMM values are then matched against theoretical values
calculated by means of a protein data base. It is an indication of a possible error in the
DNA sequence ifone or more of the measured RMM values do not correspond to any of
the predicted values. This step has the double advantage of allowing a more accurate
determination of the error in RMM and more a more specific location of the error to be
determined. Occasionally knowing the RMM value of the discrepancy together with
knowledge of the primary sequence of the digest peptide that contains the discrepancy
will be sufficient to correct the DNA sequence. This is due to the fact that amino acid
residue mutations have defined differences in RMM associated with them. It is,
however, not uncommon for multiple mutations to occur [32]. In this situation the total
discrepancy in RMM of the protein/digest peptide will be the algebraic sum of the
11
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individual mutations; if this value corresponds to that of a single mutation a mis-
correction could easily result.
A more reliable way to assign these mutations is to submit the digest peptide that
contains the modification for MSIMS analysis. Tryptic digest peptides are well suited
for MSIMS analysis as they usually fall within a suitable mass range for low energy
MSIMS analysis « 2000 Da); also they are often doubly charged and hence fragment to
produce singly charged product ions which are relatively simple to assign [34]. MSIMS
and collision induced decomposition (CID) are discussed in greater detail in sections 2.5
and 2.5 (b) respectively.
The nomenclature for peptide fragmentation along the backbone of the molecule is such
that fragment ions with the charge residing on the N-terrninus of the peptide are denoted
~, b, and c, product ions; fragment ions with the charge residing on the C-terrninus are
identified as Xn, Yn and z, ions, where n designates the amino acid residue number [35] as
illustrated in Figure 1.3.
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Figure 1.3. Nomenclature describing the fragmentation of peptides.
Identifying the sites of post translational modifications (PTMs) is also another important
application ofMS and MSIMS [36,37,38]. Common examples of such PTMs include
the removal of amino acid residues at the N or C termini after processing, acylation,
glycosylation, phosphorylation or sulfonation of certain amino acid residues. Again
accurate RMM determination may provide sufficient information to identify the PTM.
A frequent PTM is the removal of the N-terminal methionine at some stage after
synthesis which is identified by a measured RMM 131 Da lower than expected, as
encountered in chapter 3. The peptide mapping approach is also applicable to location
and identification ofPTM.
Another option to locate certain PTMs such as phosphorylation [39] or glycosylation
[40] is to use parent ion scanning. In this experiment, typically performed on a tandem
13
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quadrupole instrument, the first mass analyser (MS 1) scans for a parent ion that
fragments to produce a product ion characteristic to the modified amino acid residue.
For example phosphopeptides containing phospho serine, phosphothreonine or
phosphotyrosine yield fragment ions ofmlz 63 (P02-) and mlz 79 (P03-); glycoslated
peptides are identified by a diagnostic mlz 204 fragment ion.
This product ion is mass analysed in the second mass analyser (MS2) and subsequently
detected. This method would allow the identification of a modified peptide from, for
example, a digest peptide mixture which could then be submitted for MSIMS analysis
[41].
An accurate RMM determination can also confirm the presence or absence of a
predicted disulfide bond in a peptide or protein if the amino acid sequence deduced from
the use of DNA is available. This is possible as for each disulfide bond present the mass
of two hydrogen atoms is subtracted from the peptide/protein RMM. An example of the
confirmed presence of a predicted disulfide bond is that of the micro-antibody in chapter
6. If prior sequence information is not available, methods for locating disulfide bonds in
peptides and protein exist. These experiments normally involve reduction and
alkylation of the covalent disulfide bonds in the protein [36,42].
The analysis of hydrophobic membrane proteins presents a particular problem due to
their insolubility in the solvents typically used for ESI and MALO!. Schindler et al [43]
reported that such proteins can be dissolved in hexafluoroisopropanol or neat formic
acid and electrosprayed in a chloroform / methanol/water solution. Other workers have
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examined a number of detergents which are suitable for ESI-MS analysis and may help
to solubilize membrane proteins for analysis. The hydrophobic subunit c protein
described in chapter 4 has successfully been dissolved and sprayed in a chloroform I
methanol Iwater solvent in which the constituents are in the ratio 4/4/1.
More traditional biochemical methods for the determination of RMM and primary
sequence of proteins and peptides include sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) [44] and Edman degradation [45] respectively.
SDS- PAGE analysis is a widely used analytical technique for the separation and
characterisation of complex mixtures of proteins and for the estimation of the relative
molecular masses of proteins. Protein mixtures analysed by this method are separated
largely on the basis of electrophoresis, the movement of charged particles under the
influence of an electric field, under denaturing conditions.
The protein mixture is dissolved in a solution of SDS; this has the effect of disrupting
almost all of the non-covalent interactions of the proteins. Disulfide bonds are also
reduced by the addition of mer cap toethanol or dithiothritol (DTT). SDS anions bind to
the protein in a ratio of approximately one SDS for every two amino acid residues which
results in a large negative charge that is proportional to the RMM of the protein. The
SDS-protein complex is then subjected to electrophoresis on a polyacrylamide gel. To
aid visualisation the separated proteins are stained with silver or a dye such as coomassie
blue to produce bands on the gel. By running standards of known RMM values on the
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gel estimations of the RMM of unknown proteins can be made. The mass accuracy
achievable by this method is typically no better than 10%.
Edman degradation is a traditional biochemical method of sequencing short peptides.
Reaction between an isothiocynate compound and the N-terminal amine group of a
peptide results in the sequential removal of the N-terminal amino acid of the peptide.
The cleaved amino acid is normally characterised by HPLC. The shortened peptide is
recycled to allow removal of the next amino acid. Practically Edman degradation is
limited to approximately 30 consecutive residues as it is time consuming and requires
relativity large amounts of sample.
Edman degradation also requires an unsubstituted amine at the N-terminus; the reaction
is blocked by the presence of any substitutions. Furthermore, hydrophilic modifications
such as phosphorylation, and glycosylation are not detected by this method.
1.2 (b) Higher order structure determinations
It has been suggested that the relative extent of charging observed in an ESI spectrum
can be affected by the higher-order structure of a protein [46-50]. The high amount of
charging typically observed for denatured proteins is believed to be due to the protein
adopting a "loose" conformation thus exposing more of its potential charge accepting
sites to the solvent. Under physiological pH conditions proteins form one or more
unique conformations. Under such conditions some of the functional groups which may
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normally be charged (i.e. N-terminus, arginine, lysine and histidine) may achieve
electrostatic stabilisation by sharing a proton with another part of the protein. As a
result, the net charge on proteins may depend on the conformation of the protein. It is
considered that denatured proteins, i.e. in a open conformation, carry more charges than
tightly bound proteins. If the charge state distribution detected by ESI-MS is related to
the charge state of the protein ion in solution, then ESI-MS may be a potential probe of
the solution conformation of proteins.
The high amount of charging typically detected for denatured proteins (usually
electrosprayed in a solution of CH3CNIHzO in a 1:1 ratio plus 0.1 % HCOOH) can be
altered by several factors; all deemed to be associated with the proteins' higher-order
structure. For example the presence of disulfide bonds can lead to a lower amount of
charging and thus a shift up field in mJz values; reducing the disufide bonds leads to an
increase in the extent of charging [51,52]. Changing the pH of the solvent can also
effect the extent of charging [47,49]. Analysing proteins in a 20 mM NH40Ac (PH of
approximately 7) solvent often results in lower charging. Changes in temperature and
the addition of detergents have also been reported to affect the extent of charging [53].
Another method of probing protein conformational changes is to study the amide
hydrogen exchange rates with deuterium. Conventional methods used to follow
hydrogen exchange rates include nuclear magnetic resonance (NMR) [54] and ultra
violet (UV) [55] spectroscopies. The combination ofMS and hydrogen exchange
illustrated that almost complete hydrogen exchange in bradykinin was detectable
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[50,52]. Later studies demonstrated a large difference in the extent of exchange for a
fully denatured protein and a folded protein, suggesting that a proportion of the
hydrogen atoms in the latter were protected from exchange by the secondary and tertiary
structure [52]. Other workers have combined MS and hydrogen exchange to study the
non-covalent interaction between bovine a-Iactalbuminn and the molecular chaperone
GroEL [56].
ESI-MS can also provide information on tertiary structure by measurement of the
collision cross section of an ion. Performed in a tandem quadrupole instrument, of
quadrupole, hexapole, quadrupole (QhQ) geometry, these experiments involve
introduction of ions of known translational energy into a collision cell of known gas
pressure. As the ions traverse the cell they undergo multiple collisions, each of which
reduces their translational energy. As the ions exit the collision cell their translational
energies are measured, allowing calculation of the number of collisions they have
undergone; this value is related to their collision cross section and hence conformation
in the gas phase.
These studies indicate that cross sectional areas increase as the charge state of the ion
increases, consistent with a more unfolded gas phase ion. These studies have been
applied to small peptides (bradykinin and insulin) [57] and large proteins (serum
albumin) [58].
Under standard ESI conditions multimeric proteins normally yield ESI spectra that
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contain individual charge state distributions for each of the subunits present, as can be
seen in chapter 5 for the soluble methane monooxygenase (sMMO) hydroxylase. Under
certain conditions, however, various non-covalent interactions can be maintained in the
gas phase and thus detected by means of mass spectrometry.
Several groups have shown that myoglobin, haemoglobin, and cytochrome c form
complexes with protoporphyrin IX which can be detected by means ofESI-MS
[47,48,59,67]. When myoglobin and haemoglobin were sprayed under acidic conditions
no complex was observed; under aqueous conditions, at higher pH, complexes were
detected. The cytochrome c complex is covalently bound and thus detected under either
spraying condition. The pH of other spraying solvents has been found to be critical in
the detection of other non-covalent complexes. Ganguly et al [61] demonstrated that
pH and the presence of an organic modifier could be manipulated to produce peaks
corresponding to a 21 kDa ras protein guanosine diphosphate (ras-GDP) complex, or
only the ras-protein. At higher pH values (5-7) the complex is observed, whilst lower
pH values resulted almost exclusively in the dissociation of the complex.
MALDI-MS has found fewer application in the study of non-covalent interactions.
Suter et al [62] have demonstrated that non-covalent dimers of yeast alcohol
dehydrogenase can be detected by MALDI. Because in a MALDI experiment the
sample is dissolved in excess matrix, which may be denaturing, some non-covalent
complexes cannot be observed.
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Often MALDI-MS analysis of monomeric proteins yields peaks which correspond to
multimers of the protein, thus care must be taken when assigning signals to non-covalent
complexes.
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2.1 Introduction
The vast majority of the electrospray ionisation m/z spectra presented in this work
were acquired using a Micromass Quattro II tandem mass spectrometer of
quadrupole, hexapole, quadrupole configuration. Where greater sensitivity and
resolving power were required a Micromass Q-ToF instrument was used. The Q-
ToF mass spectrometer is a hybrid instrument of quadrupole, hexapole, orthogonal
acceleration time oftime mass analyser configuration [1].
This chapter will discuss the formation of gas phase ions by electro spray ionisation
as well as the methods employed to separate ions according to their mass/charge
ratios. Ion detection and low energy tandem mass spectrometry are also discussed.
2.2 The formation of I:as phase ions by means of electrospray ionisation mass
spectrometry
ESI can be described as the electrostatic nebulisation of a charged analyte solution,
followed by the evaporation of the resultant droplets, to produce singly and multiply
charged gas phase ions of the type [M+nH]R+from a sample having a RMM ofM .
ESI promotes little fragmentation of the ions it produces and in some situations has
been shown to retain the solution phase conformation of the analyte in the gas phase
[2,3]. For these reasons ESI is termed a "soft" ionisation technique.
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The seminal research into the use of ES as an ionisation method was performed by
Dole et al [4,5] in 1968. Dole's experiments consisted of pumping a dilute
polystyrene solution through a hypodermic needle into a cylindrical chamber through
which flowed a nitrogen bath gas at atmospheric pressure. A potential of several
kilovolts was maintained between the needle and the chamber wall. The resultant
electric field at the needle tip dispersed the liquid being pumped through it into a
fine spray of charged droplets.
Dole believed that the electrosprayed analyte solution would result in droplets
containing only one analyte ion. The constraint, however, of not having available a
mass analyser which could accommodate ions of the molecular weight range Dole
was investigating meant that direct determinations ofmlz were not feasible.
Dole, therefore, calculated the kinetic energy of the ions by measuring the retarding
potential (Vr) required to keep certain light ions from reaching a Faraday cup
collector. The ratio of mlz values were then calculated, assuming that during the free
jet expansion into vacuum the ions were accelerated to the readily calculable
terminal velocity of the bath gas, using the equation 2.1.
Using this method Dole also presented experimental evidence for the ionisation of a
protein (Zein, 50,000 Da) [6]. Dole believed that ions were formed over a series of
stages until finally, one ion would occupy one solvent droplet. This idea formed the
basis of the 'charge residue' or 'single ion in a droplet' model.
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mv2--=zeV
2 '
Equation 2.l.
where, m = Mass of ion.
v = Velocity.
z = Number of charges.
Vr = Retarding voltage.
e = Electronic charge.
This model suggests that the highly charged droplets are initially stable as the surface
tension of the droplet is greater than the coulombic repulsion between the charges.
As the droplet is subjected to evaporation the charge density on the surface increases
until the coulombic repulsion between ions on the droplet surface becomes equal to
the surface tension. At this point the Rayleigh stability [7] limit has been reached and
further evaporation leads to the violent disruption of the droplet in a process that is
often referred to as a coulombic explosion. This leads to the production of smaller
daughter droplets which undergo an identical process. Continued evaporation and
subsequent explosion of the droplets is thought to result in the dispersion of gas
phase ions in the bath gas. This process is illustrated in scheme 2.1. A portion of
this gaseous dispersion could then be expanded as a supersonic free jet into the
reduced pressure of a mass analyser.
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Evaporation
Initial droplet
Evaporation
Coulombic explosion
Daughter droplets
Process repeats ..
+ + Gas phase ionsfI
Scheme 2.t. Schematic representation of the "Charge residue" or "single ion in
a droplet" model as proposed by Dole. The schematic illustrates
the evaporation and subsequent explosion of the initial droplet.
Further evaporation and explosions are suggested to lead to
the production of gas-phase Ions,
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More recently, an alternative mechanism, field desorption has been proposed by
Iribame and Thomson [8]. They suggested that as the evaporating droplet radius
decreases the electrostatic field at the surface increases. An analyte molecule that
has accumulated sufficient charge is then able to desorb from the charged droplet
alone or in association with one or more molecules of solvent as illustrated in
scheme 2.2. In subsequent studies Thomson and Iribame presented mass
spectrometric analysis of the desorbed ions [9].
The thermodynamics of the field desorption process have been investigated by
Sakairi and Yergey [10] and used successfully to predict trends in molecular ion
intensities for amino acids analysed by ESI-MS. RolIgen et at [11] however have
questioned the Thomson and Iribame theory, as they believe that field desorption
cannot occur before the Rayleigh stability limit has been reached. They reason that a
Rayleigh explosion would occur before field desorption could take place. No one
mechanism has yet been accepted universally as the method of production of gas
phase ions from solvent droplets.
The development of ESI as a mass spectrometric technique occurred in 1984.
Yamashita and Fenn [12] demonstrated ESI-MS in the negative ion mode using a
quadrupole mass analyser of limited rnJz range and later also investigated the
interface ofHPLC and ESI-MS [13].
One of the fundamental features of electrospray ionisation is its ability to produce
multiply charged ions. It is likely that Dole observed multiply charged ions in some
of his early experiments, but misinterpreted the charge states. In 1985, Fenn and co-
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workers [13] observed dominant contributions for the doubly charged polypeptide
gramicidin S (1141 Da). More significant was the observation by Fenn and co-
workers of poly( ethylene glycol) samples of average molecular weights of up to
17,500 Da with up to 23 charges present [14].
The broad molecular weight distributions of the samples, however, meant that only
unresolved peaks were visible in the rnIz range of 500-1400 in the mass spectra.
Subsequently, the methodology was applied to large biopolymers, which overcame
this problem by having well defined molecular weights.
Fenn [IS] observed multiply protonated molecular ions of up to 40,000 Da having as
many as 45 charges. With this development came the realisation that ESI-MS could
be applied to a diverse range of biological problems.
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8nm..
Evaporation
+,
Desorption
Scheme 2.2. Schematic representation of the "Ion evaporation" model as
proposed by Thompson and Irvine.
2.3 The Micromass Quattro II tandem mass spectrometer
The Micromass Quattro II is a tandem mass spectrometer of quadrupole hexapole
quadrupole (QhQ) configuration. As a tandem instrument it can be used for both MS
and MSIMS analysis. For MS analysis ions are mass analysed in the first quadrupole
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(QI) and then diverted off axis by a high voltage lens ('Altrincham' lens) to a
photomultipler for detection as shown in Figure 2.1.
i
Post-filter 'Altrincham' lens
Ion source Detector 1 Detector 2
Pre-filters Q1analyser Q2 analyser
Figure 2.1. Schematic representation of the configuration of the Quattro II
tandem mass spectrometer operating in MS mode.
For MS/MS analysis parent ions are mass selected by QI and then accelerated into
the RF only gas filled hexapole collision cell. After undergoing CID the fragment
ions are passed into the second quadrupole (Q2) for mass analysis and detection by a
second photomultipler situated after Q2. The Quattro II is available with a wide
variety of ionisation sources including El, Cl, electro spray, APcl and thermo spray.
Electrospray ionisation was used throughout this work.
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The standard flow electro spray ionisation source of the Quattro II instrument consists
of a nebuliser, heated high voltage (H.V.) lens, ion sampling cone and skimmer
assembly. A schematic of the electro spray source is shown in Figure 2.2. The
sample is infused by a syringe driver and is transported to the source through a fused
silica capillary.
The solvent is typically composed of a volatile organic substance (acetonitrile or
Sample cone SkimmerN2 bath gas
Stainless steel 1 (jO_200V). (0-3 V)
LC pump capillary ~V 1~.~~.~O.-.~:~.~V) J
fused silica ..... .r : /'"
.::.... ....... ---.Q
'" .'. ..,-~..~ ..
. .
methanol) and water in a 1:1 mix.
HV iN2 nebulising
gas (20 LIhr)
... .
.....
• .. • •• 0.'
.... .capillary
(3-4 kV)
Cross section of HV lens
Figure 2.2. A schematic of the "Quattro II" electrospray source.
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To aid protonation, in some applications, the solvent is acidified by the addition of
0.1 - 1% of an acid e.g. formic acid.
Depending upon solution properties and the field configuration the sample solution
emerges from the source needle as a Taylor cone [16]. At higher capillary potentials
the cone becomes unstable and a liquid filament with a diameter of a few
micrometers is emitted from the cone tip. At some point the filament becomes
unstable and breaks up to form droplets. The formation of the droplets can occur in
one of several different modes [17].
The H.V. lens is shaped such that it captures a large angle of the electrospray plume
and focuses the ions towards the sampling cone. A further important point is that the
H.V. lens reduces the amount of involatile material or liquid from entering the mass
analyser, thus minimising any possible contamination of the instrument.
The ions and droplets then pass through the sample cone, which contains a small
(0.2 mm) aperture leading into the reduced pressure region of the mass analyser. The
reduction from atmospheric pressure to approximately 10-1 mbar (provided by rotary
pumps) results in a free jet expansion of the ions and gas molecules.
Finally the skimmer assembly minimises the number of any solvent molecules
entering the mass analyser. Further pumping after the skimmer assembly (provided
by turbo-molecular pumps) reduces the pressure to a value of approximately 10-5
mbar.
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As mentioned earlier, an important characteristic of the electrospray ionisation
process is that the ions produced are often multiply charged. This is an advantageous
situation, as the effective mass range of the mass analyser used is increased
considerably. Very large compounds (greater than 100,000 Da) can therefore be
detected by a mass analyser of relatively modest mlz range when using an ESI
source. For this reason the quadrupole mass analyser is commonly used with ESI.
The quadrupole also has the advantage of being simply interfaced to the ESI source
and being relatively inexpensive.
2.3 (a) The quadrupole mass filter
The Quattro II instrument utilises two high performance, research grade quadrupole
mass analysers, each incorporating a pre-filter assembly in order to reduce fringe
field effects and to protect the main analyser from contaminating deposits.
The quadrupole mass filter consists of four rods which are parallel to the z-axis and
perpendicular to the x and y-axis. Theoretically each rod should have a hyperbolic
cross-section but, in practice, cylindrical rods are satisfactory ifproperly spaced.
Two opposed rods have a potential of +(U + V cos Cl) t) and the other two,
-(U + V cos Cl) 1) where U is a fixed potential and V cos (rot) represents a radio
frequency (RF) field of amplitude (V) and frequency (Cl» as illustrated in Figure 2.3.
The stability and paths of ions within a quadrupole mass filter, in which the
separation of the opposite rods is 2ro' can be calculated from the Mathieu equations
[18].
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Equation 2.2.
Equation 2.3.
hence,
a 2U-=-
q Yo Equation 2.4.
In the transverse direction of the quadrupoles an ion will oscillate amongst the poles
in a complex fashion depending on its mlz value and the values of a and q. By
suitable choice of a and q values it can be arranged that only ions of a particular mlz
ratio will oscillate in a stable manner about the central axis; in this case all other ions
will oscillate with greater and greater amplitude until eventually they strike the rods
or pass between the rods and are lost.
The description of path stability is represented schematically in the form of a
stability diagram as shown in Figure 2.4.
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-(U+ ocoscot)
~+---(U+ Vocoscot)
ur 2•. Quadrupol ma filter rod a embly showing the application of
+( + c t) to one pair of opposing rods and the -(U + V cos co t)
tb dj nt pair of rod .
In igur 2.4. the i n r pr ented y m, lies within the region of stable oscillations
thr ugh the mass filter. The ion represented by m, lies
out i of the ar f t bl 0 cillations for these particular values of a and q and will
not p s thr ugh th m filt r.
Wher th trai hl lin 2 of lop alq enters and leaves the region of stability
ion f particul mlz which will be transmitted through the mass filter.
or lin 3 of m 11r lope smaller alq) a larger range ofmlz values will have stable
paths thr ugh th m filt r resulting in decreased resolution and increased
sen itivity [1]. onver ely. for a line (1 which passes through the apex (R) of the
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region of stability, no ions of any mlz are transmitted. To ensure that only ions of any
one selected mlz value are transmitted (i.e. maximum resolution), the ratio a/q must
be chosen such that the line passes close to R but which still lies within the region of
stability. This will give maximum resolution for the instrument, although this will be
at the cost of reduced sensitivity. Practically the resolution attainable with a
quadrupole mass filter is limited due to the low ion velocities and the positions at
which ions enter the filter [20]. It is easier to change voltages than frequencies,
therefore to transmit ions of other mlz values the frequency is kept constant but the
voltages are varied in such a way that a/q remains constant. By continuously
increasing or decreasing a and q whilst keeping a/q constant, ions of increasing or
decreasing mlz successively traverse the quadrupole assembly to give a mlz spectrum.
a
yunstable
+
O.23,1-- ----::;t"""
0.2
0.1
0.2 0.4 q 0.6 0.706 0.8
Figure 2.4. Stability diagram showing mass separation according to various
value of a and q.
43
Chapter 2: Instrumentation, Ionisation and Tandem Mass Spectrometry
2.3 (b) The Quattro II Ion detection assembly
The Quattro II uses two photomultipliers, one situated off axis after QI and the other
on axis after Q2. The principle of ion detection by the conversion of an ion current
first to electrons, then a flux of photons then to a current of electrons which is
amplified by a photomultiplier [21], is shown in Figure 2.5. The arrival of a fast ion
upon a dynode causes the emission of electrons which are accelerated onto a
phosphor screen operated at approximately 10 kV. This incidence results in the
generation of photons. The emitted light is detected by a photomultiplier and is
converted into an electric current. In the Quattro II the photomultiplier is sealed in a
vacuum tube to protect it from analyte or pump oil vapours.
Scintillator
(Phosphor screen)
Dynode Photomultiplier
Initial ion beam
r-- r---
..... ....
( ~
(
,
....
~ (, ,
- -t
Secondary
electrons
Emted
photons
Figure 2.5. Schematic of a photomultiplier detector
44
Chapter 2: Instrumentation, Ionisation and Tandem Mass Spectrometry
2.3 (e)MassLynx data system
The Quattro II instrument is operated via by the windows based MassLynx NT data
system. The software allows all source and analyser voltages to be adjusted on
screen. The software is also used for data processing and data base searches. One
particularly useful feature of MassLynx is the maximum entropy ('MaxEnt')
deconvolution algorithm [22]. The 'MaxEnt' program deconvolutes multiply
charged ESI data to a true mass scale. This is especially helpful when analysing
mixtures of proteins of pep tides or confirming the presence of minor components.
2.4. The Micromass 0- ToF quadrupole ortho2onal acceleration time of fli2ht
mass spectrometer.
The Micromass Q-ToF instrument, like the Quattro II, is a tandem mass spectrometer
capable of both MS and MSIMS analysis. It differs from the Quattro II in that it
employs an orthogonal acceleration time of flight mass analyser, which is used in
both MS and MSIMS modes of operation ofthe type first described by Dodonov et
al [23]. For MS analysis ions are passed through a RF quadrupole mass filter to a
RF hexapole collision cell, which in MS mode is not filled with collision gas, to a
two stage orthogonal acceleration single stage reflectron time of flight mass analyser
as shown in Figure 2.6.
When operating in MSIMS mode the quadrupole and hexapole act in an identical
manner to those in the Quattro II instrument i.e. the quadrupole selects the parent ion
whilst the hexapole acts as a collision cell. The benefits of using the ESI orthogonal
TOF configuration is that continuous and simultaneous detection of ions across the
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100 fold gain in sensitivity over conventional scanning mass spectrometers. The
instrument also has a m1z range in excess of 10,000 [24].
TOF
-- - --
ESI source
RF Hexapole RF Hexano le
Quadrupole Reflectron
Wide Bypass mode
Figure 2.6. Configuration of the Q-ToF instrument operating in MS mode.
2.4 (a) Time offlight mass analyser
In a time of flight mass spectrometer, ions formed in an ion source are extracted and
accelerated to a high velocity by a very short pulse of -25 kV into an analyser
consisting of a long straight drift tube. The ions travel along the drift tube until they
reach a detector. After the initial acceleration phase the velocities reached by the ions
are inver ely proportional to the square root of their m1z values.
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It is necessary to extract small pulses of ions because, using only time to differentiate
amongst the masses, it is important that the ions all leave the ion source at the same
instant with the same kinetic energy. The first step is acceleration through an electric
field (E volts). The kinetic energy of the ion is given by equation 1.
mv2
--=z.e.E
2 Equation 2.S.
Equation 2.S.follows by rearrangement,
v = ~(2z.e.E I m)
Equation 2.6.
If the distance from the ion source to the detector is d, then the time (t) taken for an
ion to traverse the drift tube is given by the equation
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t = d / v = d / ~(2e.z.E / m) = d.[~(m/ z)] / ~(2e.E)
Equation 2.7.
In equation 3 d is fixed, E is held constant in the instrument and e is a universal
constant. Thus, the flight time of an ion t is directly proportional to the square root
of mlz (equation 2.7).
t = ~(m / z) x a constant
Equation 2.8.
The resolution attainable on a typical TOF instrument is in general limited,
particularly so at higher mass. There are two major reasons for this; first the flight
times are inversely proportional to the square root of mlz thus as the mass/charge
ratio increases the difference in arrival times between ions of similar mlz values
decreases and so become increasingly more difficult to differentiate. The second
reason is that not all ions of any given mlz value will reach exactly the same velocity
or they are not all formed at the same point in the ion source. Thus even for one mlz
48
Chapter 2: Instrumentation, Ionisation and Tandem Mass Spectrometry
value the ions reach the detector over a short interval of time rather than all at once.
When the separation times of flight times is very short the spread for individual m!z
values means that there will be an overlap in arrival times between ions of closely
related m!z values.
Two methods exist for improving the resolution of a time of flight analyser. The
first is based on the work of Wiley and McLaren who developed the time-lag
focusing technique [25]. Using this method the ions are allowed a period of delay
before the accelerating voltage is applied to them. This has the effect of allowing
ions of identical mass but different kinetic energies to move away from each other.
Thus, the ions which move further away from the extraction plates experience a
greater potential than those which initially move towards the extraction plates.
Consequently, the former ions have a greater kinetic energy and hence a greater
velocity than the latter ions in the drift tube. This results in the focusing ofions with
identical mJz values at the same point thus reducing the kinetic energy spread and
improving resolution.
Another method for improving the resolution of a time of flight analyser is to make
use of a reflectron [26]. A reflectron is a homogenous electrostatic field placed at the
end of the flight path of the ions and has a polarity the same of that of the ions i.e.
positive ions experience a retarding positive potential. Upon entering the reflectron
the ions come to a stop and are then accelerated in the opposite direction.
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The reflectron is at a slight angle to the line of the flight of the ions, and when
reflected, the ions do not travel back along the same path but along a slightly
deflected one. For ions of any given mlz value the ones with greater kinetic energy
and hence velocity will have shorter drift times but will travel further into the
electrostatic field than the slower ions before being reflected. As a result the faster
ions spend more time than the slower ones within the reflectron. This focuses the
faster and slower ions so that although they leave the reflectron still with different
velocities they arrive at the detector together and the resolution is greatly improved.
There are disadvantages to using the reflectron in that the sensitivity of the
instrument is decreased through ion loss by collision and the second length of
analyser. These problems are more severe for ions of large mass and for these
reasons the reflectron is often not used in these circumstances.
TOF MS is a natural choice for pulse ionisation sources, the most important being
MALDI as it provides a complete spectrum for each event. There are however
difficulties in coupling a continuous ionisation source such as ESI to a TOF mass
analyser along the spectrometer axis without a large loss in sensitivity [27].
Fortunately a TOF analyser can tolerate a relativity large spatial or velocity spread in
a plane perpendicular to the spectrometer axis. The ions produced by an ESI source
can thus be injected into the TOF analyser perpendicular to the axis, i.e. orthogonal
injection [23, 28-30]. This geometry provides a high efficiency interface for
transferring ions from a continuous beam to a pulsed method. A second advantage is
the small velocity spread in the z direction makes high resolution easier to obtain.
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Figure 2.7. Time of flight optics in a linear instrument. A pulse of ions are
formed in the ion source (A) and then accelerated out of the source (B) into the
drift region (C). After a short while the ions have separated along the drift
region according to their m/z value. In (E) the ions with the smallest mJz value
arrive at the detector, followed by ions with increasing larger m/z values.
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Figure 2.8. Time of flight optics in an instrument equipped with a reflectron. Ions
are formed fn the fon source (A) of the same mlz value. In (B) the ions have
been accelerated but, some having different kinetic energies, they have
spread out in space. In (C) the ions approach the reflectron, which they
penetrate to different depths depending on their kinetics energies(D). In (E)
the focused ions, still with different velocities, reach the detector close
together.
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2.4 (b) Ion detection in the Q-Tof instrument
-HV+
Secondary
electrons
M icrochannel
Figure 2.9. Production of secondary electrons in a Mep.
The Q-ToF instrument employs a dual stage microchannel plate detector (Mep). The
Mep consists of an array of lead glass tubes in a solid assembly. The assembly is
sliced into wafers at an angle and polished to an optical finish. The solid cores are
removed to leave porous structures of many thousands of uniform tiny holes or
microchannels. Each microchannel acts as a channel electron multiplier. When an
ion strikes the input of the channel wall, secondary electrons are generated and
accelerated down the channel wall and additional secondary electrons are produced.
A high voltage of up to lkV is applied across the microchannel plate, the current
through the semi conductive layer supplies the electrons necessary to produce the
secondary electrons. Due to the high number of microchannels used in a Mep very
high gains are attained [31]. Further advantages of the Mep are that they are
compact, stable when exposed to air and have good signal to noise characteristics.
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2.5 Tandem mass spectrometry
As mentioned at the beginning of the chapter ESI is a relatively soft ionisation
technique as it promotes very little fragmentation and this is an advantageous
situation when RMM information is required. It provides, however, very little or no
structural or sequence information. This type of information about an ion can be
obtained by subjecting it to a tandem mass spectrometry (MSIMS) experiment.
These experiments involve the selection of the ion of interest, often called the parent
ion, in a first mass analyser. This ion is then subjected to CID to produce structurally
informative fragment or daughter ions which are separated according to their m/z
values in a second mass analyser and subsequently detected. This methodology is a
valuable way of characterising unknown compounds or confirming the presence of a
known compound. MSIMS analysis can be especially useful when selecting a
particular ion from a complex mixture as this adds a high degree of specificity.
ESI-MSIMS has been demonstrated to be a suitable method for sequencing peptide
ions [32] especially tryptic peptide ions [33,34] which are often doubly charged, thus
fragmenting to produce singly charged ions which are relatively easy to assign.
Fragmentation can also be produced in the ESI source by increasing the voltage
between the atmosphere-vacuum aperture and the first skimmer (called the cone
voltage on the Quattro II instrument). In this region, the pressure is such that
multiple collision between ions and neutrals will occur. The applied voltage
increases the energy imparted to the ions during the collisions with neutral molecules
which can result in fragmentation This type of fragmentation provides no mass
selection and as such works best with reasonably pure compounds, although it does
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provide the facility to perform MSIMSIMS (MS3) on standard tandem instruments.
Workers have successfully applied this method of fragmentation to peptide
sequencing and the identification of small molecules [35,36,37].
In the Quattro II instrument used in this study Q1 is used to select the parent ion
which is passed into the hexapole collision cell containing argon gas at a typical
pressure of approximately 5 x 10-3mbar. The collision cell is a RF only device (i.e. it
does not act as a mass filter) which, once the precursor ion has undergone CID, acts
to refocus the ions scattered by the multiple collisions. A positive ion trajectory
within an RF only hexapole will be towards the rod with a negative potential applied
to it, as the potential rapidly changes to positive the ion will be repelled back to a
central position within the rods [38]. In this manner fragment ions are focused for
maximum transmission.
A DC potential (the collision voltage) is applied to all six rods of the hexapole
relative to Q1. The polarity is such that the precursor ion is accelerated into the
collision cell. When operating in MSIMS mode all electrodes after the collision cell
automatically have the collision voltage algebraically added to their set voltages.
This is to compensate for the fact that the ions at the exit of the cell have essentially
zero energy as a consequence of the multiple collisions they have undergone and
thus have to be extracted.
The configuration of the Quattro II when operating in MSIMS analysis is shown in
Figure 2.1O.
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MSIMS analysis using the Q-ToP instrument is performed in a manner similar to that
used with the Quattro II instrument. The first quadrupole acts to select the precursor
ion which is then accelerated into the collision cell where it undergoes CID upon
impact with the collision gas. The fragment ions are mass analysed by the TOF
analyser as shown in Figure 2.11.
Detector 1
Pre- filters Q1 analyser
i
Ion source
Post-filter 'Altrincham' lens
~UD
Detector 2
Q2 analyser
Figure 2.10. Configuration ofthe Quattro II instrument for MSIMS analysis.
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ESI source
RF Hexapole
Hexapole gas
Collision cell
Quadrupole
N arrow Bypass
mode
Reflectron
Figure 2.11. Configuration ofthe Q-ToF instrument when operating in MS/MS
mode.
2.5(b) Low energy collision induced decomposition
Since being first described in 1968 [39] CID has become an accepted and routine
analytical method. The majority of low energy CID is performed in tandem
quadrupole instruments where the collision cell itself is typically a hexapole or a
octopole. The first tandem quadrupole instrument designed for analytical applications
was described by Yost and Enke [40,41]. Typically modern tandem quadrupole
instruments offer collision energies up to approximately 200eV for singly charged
ions and an mlz range of approximately 4000.
57
Chapter 2: Instrumentation, Ionisation and Tandem Mass Spectrometry
The process of collision induced decomposition (CID) of an ion to produce
structurally informative fragment ions is believed to occur via a two step process
[42,43]; activation of the ion which occurs during the interaction between the
accelerated precursor ion and the target gas, followed by unimolecular dissociation.
As the accelerated precursor ion strikes the stationary collision gas a proportion of
it's translational energy is converted into internal energy. The maximum amount of
energy which may be transferred from the translational to the internal modes (either
electronic, vibrational or rotational) of an ion in a low energy CID process is
described by the centre of mass kinetic energy EeoM-
where,
Elab = The initial kinetic energy of the ion.
m, = The mass of the target gas.
lllp = The mass of the projectile ion.
lllpi = The impact portion of the projectile ion.
The mechanism of CID depends on the time of interaction between the precursor ion
and the collision gas. The most efficient energy transfer occurs when this interaction
time between the ion and the target gas is similar to the period of the internal mode
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which is excited. This is governed by the Massey paramter tjt where t = hIE and t,
is the interaction time between the projectile and the target. During low energy CID
(typically < 200eV) the interaction time between the ion and the target gas are of the
duration of 10-13 to 10-14 seconds [44,45]. This time is comparable with that of
vibrational frequencies and thus this mode of excitation is predominant in low
energy CID.
The much higher collision energy employed in high energy CID (typically in the keY
range) results in much shorter interaction times between the ion and the target gas.
These periods are comparable with the Bohr period of an electron, thus, high energy
collisions are though to result in direct electron excitation of an ion. Redistribution
of this energy leads to vibrational excitation of the ion followed by fragmentation in
accordance with the quasi-equilibrium theory (QET) [46,47,48]. The QET postulates
that the energy from excitation is randomised over the internal modes of the ion prior
to fragmentation. Fragments are then produced by a series of competing consecutive
unimolecular decompositions.
In low energy CID experiments the nature of the target gas plays an important role in
determining the extent of fragmentation [49,50]. The use of heavier target gases
such as argon increases the maximum amount of translational energy available for
conversion into internal energy, thus increasing the extent of fragmentation. Target
gas pressure is also another important parameter which can effect the degree of
fragmentation. An increase in target pressure [51] will increase the probability of
multiple collisions between any given precursor ion and the neutral target gas. This
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will lead to a greater degree of fragmentation, although this may not always be
desirable in every experiment as low mass/charge fragment ions are not always as
informative as high masS/charge fragment ions especially when attempting to
sequence proteins and peptides.
Under low energy CID conditions the efficiency of the CID process decreases
significantly for singly charged ions having masses above approximately 800 Da due
to insufficient energy conversion to promote fragmentation [52]. For this reason the
study of singly charged ions above this mass range has historically been conducted
by high energy CID. ESI has, however, significantly increased the mass of which
useful CID data can be obtained by producing multiply charged ions. These ions
experience a collision energy of z Etab upon striking a stationary collision gas thus
increasing the amount of energy available to promote fragmentations. Useful CID
experiments have been performed using ESI on tandem quadrupole instruments for
proteins up to several thousand Daltons, although the product ion spectra produced
by the CID of highly charged precursor ions can be difficult to interpret since the
number of charges carried by the fragment ions can be difficult to determine.
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3.1 Introduction
The bacteria Nocardia corallina B-276 expresses a multi component enzyme called the
alkene monooxygenase (AMO).
The AMO has the ability to convert alkenes to optically active epoxides [1]. Epoxides
contain a three membered heterocyclic ring. Substitution on one of the carbon atoms
results in the formation of a chiral centre and hence produces an optically active
compound. Due to the high reactivity of epoxides they have been used in a large
number of organic synthetic routes to chemically and biologically important compounds.
Specific uses of epoxides include the synthesis of prostaglandins, the development of
ferro-electric liquid crystals [2] and in the synthesis ofS-arylgycidyl ethers used in the
production of P-blockers [3].
Traditional synthetic methods of producing epoxides include the Sharpless catalyst [4]
and the use ofmetalloporphyrins [5]. These methods, however, have several
disadvantages; for this reason attention has turned to biological methods of
epoxygenation.
In general, monooxygenases catalyse the direct insertion of one atom of oxygen into an
organic compound using NADH (reduced form of nicotinamide adenine dinucleotide) as
the electron donor. Monooxygenases from many micro-organisms have been purified
and studied. Only a few organisms, however, that grow on simple n-alkenes and n-
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alkanes have been considered. Probably the most studied alkane-using enzyme is the
soluble methane monooxygenase (sMMO) [6], which catalyses not only hydroxylation
of methane but also oxidation of many kinds of compounds such as alkanes, alkenes,
ethers, aromatic hydrocarbons and even carbon monoxide and ammonia.
MMO has been purified from several methanotrophs and consists of three components: a
hydroxylase, a NADH acceptor reductase and a regulatory protein.
Similarly the AMO enzyme consists of three components all of which are considered to
be necessary for activity; an epoxygenase, an NADH dependent reductase and a
coupling protein [7].
The epoxygenase consists of two subunits ofRMM 57.1 and 38.3 kDa respectively and
is believed to be the site of alkene epoxygenation. The second component called the
reductase is a 37.2 kDa protein which contains a FAD group and an Fe2S2• The role of
the final component, termed the coupling protein RMM of 12.8 kDa, is undetermined
but is essential for activity of the AMO complex.
3.2 Experimental
Mass Spectrometry
All mass spectra were recorded by means of a "Quattro II" QhQ tandem mass
spectrometer (Micromass UK Ltd, Altrincham, UK) equipped with an atmospheric
pressure ionisation source operated in the nebulizer-assisted electro spray mode. The
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potential of the electrospray needle was set at 3.5 kV and the extraction cone voltage
was varied linearly from 30V at mJz 600 to 90V at mJz 2600. The source temperature
was held at 60°C. The carrier solvent used was a 1:1mixture of CH3CNIH20 containing
0.1% HCOOH. The samples were infused using a syringe pump (Harvard modelll,
South Natic, USA) at a flow rate of SJ..lL/min.Calibration was carried out using a
solution of horse heart myoglobin or sodium iodide. Mass spectra were acquired over
the range mJz 600-2000 during a lOs scan and by operating the data system in the
multichannel acquisition (MCA) mode.
For LC/MS analysis a Perkin Elmer Model 140 A system equipped with a Cs reverse
phase HPLC column (Brownlee, 250 x 1 mm) was coupled to the mass spectrometer.
The flow rate of 50 J..lUmin was split after the column such that about 20 J..lUmin was
directed into the mass spectrometer. Native epoxygenase analysis was carried out using
a linear gradient from 20 to 90 % of solvent B over 50 min. The spectra were acquired
from mJz 600-1800 for the hydroxylase analyses and by operating the data system in the
continuum mode. Solvent B consisted of 90% CH3CN plus 0.1% trifluoroacetic acid.
All data were processed by means of the MassLynx data system. The reconstructed mass
spectra were obtained by using the Maximum Entropy algorithm.
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3.3 Results and discussion
3.3 (a) The epoxygenase
The ESI spectrum of the epoxygenase is shown in figure 3.1. The spectrum shows a
series of peaks corresponding to multiply charged ions ranging from +22 to +48 charges.
The ions correspond to a protein of RMM 38332 Da. This protein is assigned as the
smaller subunit of the epoxygenase. A second series of multiply charged ions is also
visible in the spectrum, although this is far less prominent than the first.
100 A36
A41 A39
A
A: 38332 Da ±3.5 Da
3
800 1000 1200
Figure 3.1. ESI spectrum of the epoxygenase
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The presence of more than one protein was more readily demonstrated by the
"Maximum Entropy" ("MaxEnt") deconvoluted mass spectrum. This clearly shows the
presence of the protein at 38331 Da already assigned as the smaller subunit of
epoxygenase and another protein of RMM 57081 Da. This protein is assigned as the
larger subunit of the epoxygenase. The "MaxEnt" deconvoluted mass spectrum of the
epoxygenase is shown in Figure 3.2.
100 38331 "x211
Smaller epoxygenase-: subunit
%
8372
Larger epoxygenase 57081
subunit
<,
0 Mass40000 50000 60000
Da
Figure 3.2. "MaxEnt" deconvoluted mass spectrum of the epoxygenase
Improved detection of the larger subunit of the epoxygenase was achieved by submitting
the epoxygenase to HPLC-ESI-MS.
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The total ion current (TIC) profile of the epoxygenase is shown in figure 3.3. The two
expected subunits of the epoxygenase were located in the main peaks of the TIC profile
(retention times 30.2 and 36.0 minutes respectively). The minor peaks on the TIC
profile were found to consist of impurities.
10
Smaller epoxygenase 30.20
subunit ~
%
10.00 20.00 30.00
35.98
Larger epoxygenase
subunit
/
40.00 50.00 Time
Figure 3.3. Total ion current (TIC) profile of the epoxygenase
The spectrum which produced the peak that eluted at 30.2 minutes of the TIC profile is
shown in figure 3.4.
The spectrum shows a series of peaks corresponding to multiply charged ions of a
protein ofRMM 38331 Da, this protein is assigned as the smaller subunit of the
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epoxygenase as identified in the direct injection of the epoxygenase as shown in figure
3.1.
The measured RMM of the smaller subunit is 38331 Da. A comparison of this value
with the predicted RMM of38462 Da, as calculated from gene sequencing, suggests that
the N-terminal methionine residue of the polypeptide have been cleaved. If one takes
this process into account the predicted RMM of the smaller subunit is 38331 Da. This
value is in excellent agreement with the measured RMM, and suggests that the
published primary sequence of the smaller subunit of the epoxygenase is correct
The ESI spectrum that produced the peak eluted at 36.0 minutes of the TIC profile of the
epoxygenase is shown in figure 3.5.
The spectrum shows a series of peaks which correspond to multiply charged ions (32 to
74 charges) of a protein of measured RMM 57080 Da. This protein is assigned as the
larger subunit of the epoxygenase.
74
Chapter 3: Characterisation of the Alkene Monooxgenasefrom Norcardia Corallina B-276
100 A36A39 A34
" /
A4l
A42
% A43
A44
A32
A3l A25 A24,
A22
A23
Figure 3.4. The ESI spectrum that produced the peak eluted at 30.2 minutes of the
TIC profile of the epoxygenase
Again comparison with the predicted RMM of 57211 Da, as calculated by gene
sequencing, suggests that the N-terminal methionine of the polypeptide has been
cleaved. This result suggests that the published primary sequence of the larger
epoxygenase subunit is also correct.
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A68
A47
,
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A69 A46, A43
A70 ...
A37
A64A62 AS9- / ASS
AS2
/
100
A65
Figure 3.5. ESI spectrum that produced the peak eluted at 36.0 minutes of the TIC
profile of the epoxygenase.
3.3 (b) The Reductase
The single component reductase was analysed by direct injection into the mass
spectrometer. The ESI spectrum of the reductase is shown in Figure 3.6.
The spectrum shows a series of peaks which correspond to multiply charged ions of the
charge states +23 to +48. The ions correspond to a protein ofRMM 37152 Da. The
single component reductase is easier to visualise in the "MaxEnt" deconvoluted mass
spectrum as shown in figure 3.7.
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10 A39 A37
A40
A42
A:37152 Da
A35
A43 A34
%
A32
800 1000 1200 1400 1600
Figure 3.6. ESI spectrum of the reductase
100 37152
%
30000
Figure 3.7. "MaxEnt" deconvoluted mass spectrum of the reductase.
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The predicted RMM, as calculated from gene sequencing, is 37282 Da. Ifremovalof
the N-terminal methionine occurs giving a RMM of37151 Da, then this value is in good
agreement with the measured RMM of37152 Da. These data suggest that the published
amino acid residue sequence of the reductase is correct, although its predicted RMM
reported by Saeki and Furuhasi [8] of37828 Da appears to have been miscalculated.
3.3 (e) Tile coupling protein
The ESI spectrum of the coupling protein is shown in Figure 3.8. The protein is
prepared in the presence of benz amidine, a serine protease inhibitor, since in its absence,
it has been observed that cleavage of the coupling protein occurs resulting in loss of all
AMO activity [9].
A similar cleavage of protein B, the equivalent protein from the sMMO complex has
been observed during its purification which also results in the loss of activity of the
enzyme.
The ESI spectrum of the coupling protein, prepared in the presence of benz amidine,
shows the presence of more than one series of multiply charged ions. This suggests that
benzamidine does not completely stop the cleavage of the coupling protein.
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%
A12
A14
12 A10
11
A8A13
,B8
Figure 3.S. ESI spectrum of the coupling protein prepared in the presence of
benzamidine
The presence of several proteins is demonstrated in the "MaxEnt" deconvoluted mass
spectrum of the coupling protein as shown in Figure 3.9.
The coupling protein has a predicted RMM of 12985 Da, as calculated from gene
sequencing. Removal of the N-terminal methionine, as seen for the other subunits of the
AMO, would result in a predicted RMM of 12854 Da. This value is higher than any of
the proteins detected in the spectrum of the coupling protein.
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100 11980.0
12021.6
/
%
3993.5 12167.0
/
Figure 3.9. "MaxEnt" deconvoluted mass spe~trum of the coupling protein
prepared in the presence of benzamidine
The most prominent proteins detected by ESI-MS had RMM values of 11980.0, 12021.6
and 12167.0 Da respectively. If the predicted amino acid sequence is correct the 12167
Da protein is most likely to have arisen from a cleavage between Lys4 and GluS and
residues Phel14 and Lysl15. The 11980 Da is most likely due to a single cleavage
between residues ValS and Thr9. There are two possible cleavage reactions which could
have resulted in the 12021.6 Da protein as illustrated in Table 3.1.
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Measured RMM Residues Predicted RMM Difference
(Da) (Da)
12167.1 5-114 12167.6 0.5
12021.6 3-111 12020.4 -1.2
12021.6 5-113 12020.4 -1.2
11980.0 9-116 11980.4 0.4
Table 3.1. Measured RM:Mvalues and possible cleavage sites in the proteins
present in the preparation mixture containing benzamidine.
Purification of the coupling protein in the absence of benz ami dine resulted in the
production of an inactive protein (in terms of AMO epoxygenation activity). The ESI
spectrum of this preparation is shown in figure 3.10.
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100
975.9
%
894.2 1073.5
825.7 1192.6
773.
1465.4
1341.5
1532.9 1788.6
Figure 3.10. ESI spectrum of the coupling protein prepared in the absence of the
serine protease inhibitor benzamidine
The ESI spectrum of the coupling protein prepared in the absence of benz ami dine shows
a complicated mixture of multiply charged ions, suggesting that the coupling protein has
undergone further cleavage when prepared without benzamidine. The "MaxEnt"
deconvoluted mass spectrum shows the presence of several cleavage proteins as shown
in figure 3.11.
The most prominent proteins in the spectrum are 12627.5 Da, 12167 Da, 11590.0 Da
and 10723.0 Da. The 12167.0 Da species is probably the same species observed as the
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material purified in the presence of benz ami dine. The 11590 Da peptide was not
observed when the protein was purified with benzamidine.
100 10723.0
%
11590.0
12627.5
Ol~~~~~~~~~~~~~~~~~rnass
5000 10000 15000
Figure 3.11. "MaxEnt" deconvoluted mass spectrum of the coupling protein
prepared in the absence of benzamidine.
Analysis of the amino acid sequence of the coupling protein indicates that the 11590 Da
peptide may have arisen from a cleavage between residues Arg113 and Phe114. The
likely cleavages of the coupling protein which would result in the 10723.0 Da species
are illustrated in Table 3.2.
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The 12627.0 Da species could not be identified as a cleavage product and could
represent an impurity that co-purified with the coupling protein.
It is most likely that the 11980 Da and/or the 12021.6 Da species are the active form/s
of the protein when purified in the presence of benz amidine since the 12167 Da peptide
was present whether benzamidine was added or not.
If the 11980 Da species is the active form of the coupling protein this suggests that
possibility the C-terminus of the coupling protein is essential for the activity of the
coupling protein as this is retained in this cleavage protein. There are two possible
consequences for the cleavage of the coupling protein at the N-tenninus. First, that the
N-tenninus is simply not required for activation of the protein, or that cleavage is
required for activation of the protein in a similar way to that observed for the activation
of chymotrypsinogen to chymotrypsin.
Alternatively the 12021.6 Da cleavage protein could be the active form of the coupling
protein as this was only observed when the coupling protein was prepared in the
presence of benz amidine.
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Measured RMM Residues Predicted RMM Difference
(Da) (Da) (Da)
12627.8 ??? N/A N/A
12167.8 5-114 12167.6 -0.2
11590.2 9-113 11590.0 -0.2
10723.1 10-106 10723.0 -0.1
10019.8 7-97 10019.2 -0.6
10019.8 10-100 10019.2 -0.6
7091.0 49-109 7090.0 -1.0
7091.0 50-110 7090.0 -1.0
6668.6 46-103 6668.5 -0.1
Table 3.2. Measured RMM values and possible cleavage sites of the proteins
present in the preparation mixture when benzamidine was not
present.
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3.4 Conclusions
The good agreement between the measured and predicted RMM values for each of the
component proteins of the AMO suggests that the published amino acid sequences are
correct.
All the components have at some stage after synthesis been processed by the removal of
the N-terminal methionine.
Analysis of the coupling protein has identified cleavage reactions which lead to
inactivation of the protein. The inclusion of benz ami dine during the purification of the
coupling protein prevents cleavage at the C-terminus in the production of the 11980 Da
protein which could prevent inactivation of the coupling protein.
A similar cleavage reaction was observed at the N-terminus of protein B ofsMMO
which resulted in inactivation of the enzyme. Cleavage of protein B could not be
prevented by addition of a protease inhibitor to the preparation
Alternatively benzamidine could prevent further cleavage of the 12021.6 Da protein
which could be the active form of the protein.
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4.1 Introduction
The neuronal ceroid lipofuscinoses, known collectively as Batten disease, are a group of
neurodegenerative lysosomal storage diseases affecting humans and other animals [1].
Three main forms of the human disease exist and are classified by the age of the victim
upon onset of the disease. These are; an infantile form (INCL or CLI) which occurs
most frequently in Finland, a late infantile form (LINC or CLN2) and a juvenile form
(JNCL or CLN3) [2]. Children affected with the disease lead a normal life until at
different ages they develop increasing dementia, blindness and seizures culminating in
premature death. Collectively these diseases have been estimated to occur at a rate of
one in every 12,500 births world wide [3].
The various forms of Batten diseases are proteinoses in which specific hydrophobic
proteins are stored in lysosome-derived organelles. This initial discovery was made in a
well described form of Batten disease in a flock of sheep deliberately bred and
maintained as a model of the human disease. Analysis of the storage bodies isolated
from fresh tissue revealed that more than 70% of their mass was protein, the rest being
lipids typical of lysosome-derived organelles [4].
Initially the major storage body was difficult to identify as it is insoluble in all but a few
solvents. Direct N-terminal sequencing eventually revealed that the major storage body
protein had the same complete sequence as subunit c of mitochondrial ATP (adenosine
triphoshate) synthase [5].
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These results established that the sheep disease, ovine ceroid lipofuscinosis, is a
proteinosis in which subunit c of ATP synthase, an hydrophobic inner mitochondrial
membrane protein is abnormally stored in lysosome derived organelles. Subsequent
studies showed that a protein with an identical amino acid residue sequence to that of
complete subunit c is also stored in the late infantile and juvenile human diseases [6).
N-terminal sequencing also established subunit c storage in affected English setter,
Border collie and Tibetan terrier dogs [7]. The relative amounts of subunit c in storage
bodies varies in these diseases and there is evidence of co-storage of other proteins in
some forms.
The metabolic basis for the accumulation of subunit c in the ceroid lipofuscinoses is
currently unknown. The specificity of the storage suggests that the concept underlying
Batten disease are lesions that effect the turnover of subunit c in such a manner that it
accumulates in storage bodies [6]. Possibilities include, the over production of subunit c
or a modification of subunit c which is specific to the disease and causes accumulation.
In particular Katz and Rodrigues [8] have suggested that the stored subunit c carries a
trimethyl-modification of one of its two lysine residue (Lys 43), although this finding
has been questioned by others [9].
Subunit c is found in mitochondrial ATP synthase (FI-Fo-ATPase) which is a
mutli-subunit enzyme complex that utilises a transmembrane proton gradient to
synthesise ATP [10). It consists of two domains linked by a stalk assembly (called the
y-subunit) : a hydrophilic part, FI, which is the catalytic site of ATP synthesis and a
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transmembrane portion, F0' which catalyses proton translocation events (Figure 4.1.).
The number of F, subunits is known to be variable and species specific. Subunit cis
known to be present in multiple copies, in the F0 subunit, which are proposed to form the
components of an oligomeric proton channel. The mechanism of proton conduction is
not known but a major role has been attributed to GIu-58 in mitochondrial subunit c.
a-subunit
p-subunit
y-subunit
Lipid
/bilayer
Figure 4.1. Schematic representation of the Mitochondrial ATP synthase
(FJ-Fo-ATPase) spanning the inter mitochondrial membrane.
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The subunit c protein is also known to be the site of binding of several diagnostic
inhibitors of the ATP synthase such as N,N'-dicyclohexylcarbodiimide (DeeD).
DeeD is thought to block ATP synthesis by interfering with the utilisation of the proton
gradient.
Q-N-C-O
DCCD
R-COOH
Carbonyl
o (+206Da)
R-~-OQ-NH-6=N-Q
R-substituted dicyclohexyl-
O-acylisourea
R-i=O (+2050a)
Q-NH-TI-N-Q
o
R-substituted dicyclohexyl-N-acylurea
Scheme 4.1. Schematic of the intramolecular rearrangement of an R-substituted
dicyclohexyl-O-acylisourea to an R-substituted dicyclohexyl-N-acylurea
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DCCD interacts with a specific ~-carboxyl group in the Fo-subunit [11]. The reaction
product is an unstable O-acylisourea (+206 Da) which by intramolecular rearrangement
yields a stable N-acylurea with a final mass increase of205 Da. [12] as illustrated in
Scheme 4.1.. Studies of the correlation of [14C]-DCCD binding with heart mitochondria
show that the [14C]-DCCD binding with the equivalent of only one subunit c out of the
circular array of9-12 subunit c present in Fo correlates with maximal inhibition of ATP
synthase activity [13]. There is, however, a requirement for at least an additional2-3
moles of DCCD per mole of FIFo ATP synthase for incorporation of 1 mole of e4C]-
DCCD per mole FIFoATP synthase. The function of the excess DCCD is unknown but
is usually attributed to non-specific hydrolytic or non-productive condensation reactions
which are not inhibitory.
Subunit c is thought to fold in the Fo sector of the ATP synthase like a hairpin with two
membrane traversing a-helices as shown in Figure 4.2 [14]. Residues in both membrane
traversing helices are labelled by hydrophobic agents that are thought to react with the
apolar phase of the lipid bilayer. Proton transport through the membrane along F,
probably induces long-range conformational changes that pass via the stalk to the
catalytic sites in FI to drive ATP synthesis.
Mitochondrial subunit c is both difficult to extract and purify due to its hydrophobic
nature. Alternatively CLP can be extracted in high yield and purity from the lysosomal
storage bodies of sheep affected with Batten disease [5]. CLP has significant advantages
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therefore as a model system of mitochondrial subunit c and its interactions with
inhibitors for ESI-MS studies [15].
In order to span the inner mitochondrial membrane subunit c is, as mentioned
previously, hydrophobic. Hydrophobic proteins are not routinely characterised by ESI-
MS as they are generally insoluble in the solvents used in the ESI process. ESI is also
intolerant of detergents which are used quite often to solubilize such proteins. Some
hydrophobic proteins can, however, be characterised by ESI-MS when dissolved in
suitable solvents such as chloroform/methanol/water (CfM/W) [16]. This solvent
system is used in this study both in the extraction of the CLP and subunit c and as the
solvent system used for the ESI.
4.2 Experimental
Mass spectrometry
All mJz spectra were acquired by means of a "Quattro II" tandem mass spectrometer of
QhQ geometry operated in the positive ion mode. The instrumental conditions were as
described in chapter 3. The CLP was diluted to approximately 2pmJmL in
chloroform/methanol/water (CIM/W) before ESI analysis.
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Purification of the ceroid lipofuscinosis protein
Lysosomal storage bodies were isolated from the liver of sheep affected with ceroid
lipofuscinosis as described by Palmer et al [17]. Purified eLP was extracted from the
bodies by chloroform/methanol extraction [5].
Inhibitors and incubation conditions
eLP solutions were diluted with an equal volume of eIM/W and DeeD added to give a
100: 1 molar ratio. The solutions were then incubated at room temperature for 90 mins
or 18 hours. Samples of the incubation mixture were then further diluted with elMlW,
centrifuged at 14,000g for 1 min and immediately submitted for ESI-MS analysis. eLP
solutions of differing pH were made by mixing eLP solutions containing ammonium
acetate at pH 7-7.5 with trifluoroacetic acid (IF A) in the CIMIW dilution mixture at
levels of 0.1% v/v IF A or 1.0% IF A, before incubation with the DCCD.
Bovine heart mitochondrial subunit c extraction
AI Standard procedure
1ml of beef heart mitochondrial suspension (approximately 25 mg) was extracted with
25 ml CIM by stirring at 4°e overnight. The extraction mixture was filtered twice
through a glass fibre filter (Whatman GF/e) using a glass filtration system (Millipore).
The single phase filtrate was washed with 0.2 vol. water by vigorous shaking for Smins
and the emulsion allowed to stand for phase separation and then centrifuged at 4000g for
15 mins. The aqueous layer was removed by aspiration together with any lipid layer
present at the interface of the solvent layers.
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The lower phase was then washed with CIM/W (1: 1v/v), using one third the volume
used in the first wash. The lower layer was then used for ESI-MS analysis.
El Rapid micro-extraction method
A procedure was devised which is suitable for small samples (1-3 mg of protein) using
micro centrifuge tubes and a bench micro-centrifuge. 0.1 mL heart mitochondrial
suspension was extracted with 1.5 mL CIM by vigorous shaking for 20 min at room
temperature in a 2.0 mL polyethylene micro-centrifuge tube. The resultant suspension
was allowed to stand for 1 min and then centrifuged at 20,000 g for 3 min at room
temperature. The floating mitochondrial layer present in a small aqueous surface layer
was displaced to the side of the tube by a small spatula (metal or polyethylene) and the
extract (approximately 1.5 mL) was poured directly into another micro-centrifuge tube.
Water (0.3 mL) was added and after vigorous mixing for 1 min the mixture was
centrifuged at 20,000g. The upper aqueous layer and any interface film is removed
carefully by aspiration. The lower chloroform layer was then washed with 0.1 mL
methanol/water (1: 1 v/v) as before and the lower chloroform layer obtained after
centrifugation was used directly for ESI-MS analysis. The mitochondrial floating layer
left after the initial extraction can be re-extracted by immediate addition of 0.05 mL
water followed by 0.75 mL ofCIM.
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4.3 Results and discussion
4.3 (a) ceroid lipofuscinosis protein
Figure 4.3. shows the ESI spectrum of the liver ceroid lipofuscinosis protein (CLP). The
spectrum shows peaks corresponding to the 3+ to the 8+ ions of a protein of measured
RMM 7650.2 Da ± 0.3 Da, this protein is assigned as the CLP. The measured RMM
value disagrees with the predicated RMM value of7608.0 Da, calculated by means of
gene sequencing [18], by +42.2 Da. The increase in RMM could be explained by a
trimethylation (+43 Da) or by an acetylation (+42 Da) of an amino acid residue. Other
explanations for discrepancies in RMM include amino acid residue substitutions such as;
Gly - Val (42 Da), Leu - Arg (42 Da) and lIe - Arg (43 Da).
The spectrum also shows another series of peaks which correspond to multiply charged
ions of a protein ofRMM 7666.2 Da. This is assigned as being oxidation of one of the
amino acid residues, such as one of the methionine residues [19] present in the CLP.
All attempts to follow the standard procedure of cleaving or digesting the protein in
order to produce a cleavage/digest peptide map to aid in the location and identification
of the RMM discrepancy were unsuccessful. This was due to the protein being
hydrophobic and thus insoluble in the solvent systems employed for chemical cleavage /
enzymatic digestions.
An MSIMS experiment of the intact subunit c was therefore undertaken to try and
locate and identify the discrepancy in RMM.
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The MSIMS spectrum of the [M+5H]S+ion of the CLP protein is shown in Figure 4.4.
The most prominent fragment ions are a series of quadruply charged b and singly
charged y ions as labelled in Figure 4.4. The singly charged y ions correspond to the y,-
YIO fragment ions which originate from the C-terminus. The fragment ions Y'-Y6 are
accompanied by a satellite ions of + 16 Da.
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Figure 4.3. ESI spectrum of the liver ceroid lipofuscin osis protein.
100
Chapter 4: Characterisation The Ceroid Lipofuscinosis Protein.
o/c b4+~4+68 JI'
b6t b6t
b4+ 4+' bn"
Y2 60
6l
b~
/
\b ~ bn4+Y3 ~
y,
59 ,
I'
Y4
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400
1
Figure 4.4. MS/MS spectrum of the [M+5H]s+ ion of the ceroid lipofuscin osis
protein.
This suggests that the 7666.2 Da species present in the ESI-MS spectrum assigned as
being oxidation arises from the e-terminal methionine amino acid residue of the eLP
The most prominent peaks in the MSIMS spectrum correspond to a series of fragment
ions from bS94+ to b734+. The spectrum also contains a further three series of peaks of
much lower intensity which correspond to b/ to b.,", b," to b2/+ and b463+ to b6/+
fragment ions. The sequence coverage obtained by the MSIMS analysis of the
[M+5H]S+ion of the eLP is illustrated in Figure 4.5. Overall the MSIMS experiment
confirmed approximately 80% of the primary sequence of the eLP.
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The partial sequence coverage is consistent with the +42.3 Da modification being
present on amino acid residues 30-46. This section of the amino acid sequence is not
covered by the MSIMS data. The data are consistent however with acetylation at
Lys43, Ser41 or Arg38 or alternatively trimethylation at Lys43. Previous ESI-MS
studies [20] have shown through the application of amino group reagents such as 1-
fluoro-2,4-dinitrobenzene and phenyl-isocyanate that Lys-43 is already modified and
this amino acid remains the prime candidate for further investigation.
4.3 (b) Bovine heart mitochondrial subunit c.
The next stage in the investigation was to establish whether the +42.3 Da modification
present on the eLP was due to Batten disease or was it present upon the undiseased
subunit c protein. Bovine heart mitochondrial subunit c was therefore extracted and
subjected to ESI-MS analysis as shown in Figure 4.6.
The BSI spectrum of bovine heart mitochondrial subunit c is dominated by a number of
peaks corresponding to singly charged ions in the range 600-1100 m/z. These are
assigned as being lipids and phospholipids which were also extracted during the
purification of the subunit c and are characteristic ofES! spectra of bovine heart
mitochondrial subunit c extracted in this manner.
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The spectrum shows peaks which correspond to the 6+ to 3+ ions of a protein of RMM
7650.3 Da. This protein is assigned as bovine heart mitochondrial subunit c, confirming
that the +42.3 Da is found on subunit c extracted from a healthy animal as well as on the
ceroid lipofuscinosis protein (ovine and bovine subunit c share an identical amino acid
sequence).
The finding that the +42.3 Da modification, whether it be acetylation or trimethylation
or an amino acid residue substitution, is present on both the normal and diseased subunit
c is in contrast to the results of Katz et at [8]. They have suggested that the eLP contains
a trimethylation (TML) of one of its two lysine residues but that the normal subunit c in
mitochondrial ATP synthase does not contain elevated amounts ofTML.
The oxidised component of the subunit c is considerably more significant than was
found in the ESI-MS spectrum of the eLP, indeed the peaks corresponding to the
oxidised subunit c are the prominent peaks in the 6+ and 5+ charge state clusters.
Invariably the subunit c purified by the standard over night extraction was found to
contain high levels of the oxidised component. As oxidation of subunit c may modify
the enzymatic function of subunit c in the ATP synthase complex, or its status upon
extraction, it is of interest to establish the normal condition of subunit c in mitochondria.
A rapid micro extraction procedure was therefore devised where the extraction time was
reduced to 20 mins as opposed to the standard over-night extraction. The ESI spectrum
of mitochondrial subunit c extracted by the rapid micro extraction procedure is shown in
Figure 4.7.
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950.7
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951.8
Figure 4.6. ESI spectrum of bovine heart mitochondrial subunit c extracted by the
overnight method. Inset shows expanded mJz range which contains the
4+ charge state cluster of subunit c and its oxidised component.
The spectrum in Figure 4.7. shows the characteristic lipids and phospholipids as
observed in the ESI spectrum of the mitochondrial subunit c extracted by the standard
overnight extraction procedure. Also present are peaks corresponding to the 3+ to 6+
ions of subunit c of measured RMM 7650.2 Da. Examination of the charge state
clusters revealed no or very low intensity peaks which correspond to what is believed to
be the oxidised form of subunit c. It is apparent from these data that a significant amount
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of oxidation of subunit c occurs during the overnight extraction procedure. The
measured RMM of the subunit cremains 7650.2 Da suggesting that it contains the same
post translational modification or amino acid substitution as the ceroid lipofuscinosis
protein and overnight extracted bovine heart mitochondrial subunit c.
1
760.9
7650.2
%
]666.4
.9
o mass
6500 6750 7WJ 72fJCJ 7500 7750 SOOO 8250 6500 8750 9000
701",
A4+
Figure 4.7. ESI spectrum of mitochondrial subunit c extracted by the rapid
extraction method. Inset shows the deconvoluted mass spectrum.
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4.4 Summary
The work presented in this chapter so far has shown that:
• The hydrophobic ceroid lipofuscinosis protein can be analysed by ESI-MS when
dissolved in a solvent system composed of chloroform/methanol/water in the ratio
4/4/1 plus 0.1% HeOOH.
• The eLP has a measured RMM of7650.3 Da ±0.4 Da
• The RMM calculated from the DNA sequence for subunit c is 7608.0 Da. The
difference between the measured and the calculated RMM is +42.3 Da.
• The discrepancy in RMM could be explained by the presence of one acetyl (+42 Da),
or a trim ethyl (+43 Da) modification ofan amino acid residue. Alternatively an
amino acid residue substitution such as Gly to a Val (42 Da), Leu to a Arg (42 Da)
or lIe to a Arg (43 Da) could account for the discrepancy.
• MSIMS analysis confirmed approximately 80% of the primary sequence of the eLP
and was consisted with the modification being present on amino acid residues 30-46.
• Bovine heart mitochondrial subunit c was successfully extracted and analysed by
ESI-MS.
• The measured RMM of the bovine heart mitochondrial subunit c was 7650.2 Da,
indicating that the same modification is present as is found on the eLP.
• A short term extraction (20 mins) produced subunit c which contained little or no
oxidation.
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4.5. Interactions with DeeD
From previous investigations [12] the expected eLP-DeeD complexes at Glu-58 are the
O-acylisourea (+206 Da) and/or the stable N-acylurea (+205 Da). Interaction ofCLP
with DeCD in aprotic solvents revealed no significant interaction on ESIIMS analysis
and no formation ofa CLP-DCCD complex (+205 Da or +206 Da) was detected.
Inclusion of water in the incubation medium as described by Fillingame et al. [20] was
required for the formation of CLP-DCCD complexes and Figure 4.8. shows that other
addition products are formed.
Figure 4.8. (A,B,C) shows the ESIIMS spectra obtained after incubation of CLP with
DCCD. In addition to the major peak ofCLP at 7650 Da and its oxidation product at
7666 Da (+16 Da), the following new species are identified:
(a) The DCCD addition complex (+206 Da) at 7856 Da and its oxidation product at
7872 Da (+206 Da + 16 Da). This is the product expected, presumably by addition
to GIu-58, but its levels are variable and it is not a major product.
(b) A major addition product at 7692 Da (+42 Da) and its oxidation product at 7708 Da
(+42Da + 16 Da). This is due to a DCeD-catalysed acetylation of eLP utilising the
acetate in the ammonium acetate buffer (see below).
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(c) A major addition product at 7898 Da (+206 Da + 42 Da) and its oxidation product at
7914 (+206 Da + 42 Da + 16 Da) which is the result of DCCD addition (+206 Da) to
the initial acetylated product at 7692 Da (+42 Da).
%
B:7692.2
7707.8
/
1
A:7650.3 D:7898.3
C:7856.0 ,,7913.9
7593.0
7400 7500 7600 7700 7800 7900 8000 8100 8200
Mass (Da)
Figure 4.8.A. Deconvoluted mass spectrum of CLP incubated with DeCD at a mole
ratio of 10:1 for 18 hours at 4°c. CLP dissolved in C/MIW containing
no TFA.
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Figure 4.8.B •Deconvoluted mass spectrum of eLP incubated with DeeD at a
mole ratio ofl0:l for 18 hours at 4°c. eLP dissolved in elM/W
containing 0.1 %TFA.
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Figure 4.8.e • Deconvoluted mass spectrum of eLP incubated with DeeD at a
mole ratio of 10:1 for 18 hours at 4°c. eLP dissolved in eIMIW
containing 1.0% TFA.
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Kinetic studies of the interaction of DCCD with CLP under these conditions (high
acetate concentration, high DCCD:CLP ratio of 100: 1) indicate that the primary reaction
is the DCCD-catalysed acetylation leading to the formation of the species at 7692 Da
(+42 Da) and its oxidation product. This is followed by DCCD addition (+206 Da) to
give the acetylated-CLP-DCCD product and, exceptionally, a further DCCD addition
(+206 Da). The initial, apparently direct, formation ofCLP-DCCD (7856 Da) is a
relatively minor reaction pathway but becomes more significant at very high
DCCD:CLP ratios. In view of the predominance of the DCCD-catalysed acetylation
reaction, however, it is difficult to determine whether the observed CLP-DCCD complex
formation occurs directly or whether it is a deacylation or transacylation product of
acetyl-CLP-DCCD (7898 Da).
Effects of pH and DCCD:CLP ratios on DCCD interaction.
Increased acidity of the incubation medium leads to a decline in the level of the CLP-
DCCD complex at 7856 Da such that at 1% TFA (Figure 4.8C), the acetylated-CLP
(+42 Da) is the predominant product with only minor amounts of the eLP-DeeD-
acetylated complex (+206 Da +42 Da). Little or no DeeD-eLP complex (+206 Da) is
present. The major product at low DCeD:eLP ratios (10:1 or less) is the acetylation
product at 7692 Da (+42 Da) and its oxidation products. Formation ofless than 5% of
the DeeD-eLP complex (+206 Da) or the acetylated-CLP-DCCD complex (+42 Da +
206 Da) is observed, even on complete conversion of Cl.P, Conversely, at very high
DCCD:CLP ratios (>200:1), complete modification ofCLP has been observed leading
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to two major products: invariably one at 7898 Da (+42 Da +206 Da) and occasionally a
novel species at 8104 Da (+42 Da +206 Da +206 Da) with their usual oxidation products
(data not shown). Under these conditions the yield of initial acetylation product (+42
Da) is markedly reduced. The second DeeD product has not previously been described
and its interaction site has not been established.
In all studies involving the formation ofeLP-DeeD adducts, the mass increase is +206
Da in the large majority of cases. Although this suggests that the product is the 0-
acylisourea derivative, (+206 Da), the resolution achievable with the "Quattro II" mass
spectrometer is insufficient to allow a definitive demonstration of the formation, if any,
of the N-acylurea derivative (+205 Da).
DCCD-catalysed Acetylation and the Acetylation Site
To establish that the source of the acetyl group (+42Da) is the ammonium acetate
buffer, control experiments were carried out with eLP that had been extensively washed
by the method ofFolch et al. [21] to reduce the acetate content. Such preparations show
little or no formation of the 7692 Da species (+42 Da) on incubation with DeeD but
this reaction is restored on addition of ammonium acetate. Similarly, ammonium
acetate restores the DeeD-catalysed acetylation reaction to eLP prepared in the absence
of ammonium acetate, thus confirming that the ammonium acetate buffer is the source of
the acetyl group (+42 Da).
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The possible role of Cys-64 as an acetylation site on CLP or as a transient site in a
trans acetylation reaction has been investigated by titration of Cys-64 with 2,3-
dimethoxy-6-methyl,I,4-benzoquinone (UQO) to form a CLP-UQO complex (+ 180 Da)
as previously described [22]. Incubation of CLP-UQO with DCCD leads to the
formation of the acetylated product (+ 180 Da + 42 Da) and the acetylated-CLP-UQo-
DCCD product (+180Da + 42 Da +206 Da) as shown in Figure 4.9. It is concluded that
Cys-64 is unlikely to be involved in the DCCD-catalysed acetylation reaction or any
consequent transacylation reaction.
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Figure 4.9. Deconvoluted mass spectrum showing the effects of 2,3-dimethoxy-6-
methyl-l,4-benzoquinone on the reaction of CLP with DeCD.
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eID analysis ofthe acetylated eLP species ofRMM 7692 Da was performed on the
[M+5H]5+ ion of the modified species. This analysis establishes that the acetylation is
associated with one of the first nine amino acids in eLP but it was not possible to define
the particular amino acid involved. Lys-7 and N-terminal aspartate appear to be the
prime candidates.
Other DCCD-catalysed acylations
The DeeD-catalysed acylation is not limited to the acetylation reaction (+ 42 Da).
Under appropriate conditions, DeeD-catalysed acylation of eLP by the fatty acids
myristic, palmitic, oleic and stearic acids has been observed. Incubation of eLP with
DeeD and the ammonium salts of fatty acids under standard conditions (eLP diluted
1:1 with eMW; 50 mM ammonium acetate) led to the formation of'acetyl-Cl.P (+42
Da) only. No fatty acid or DeeD adducts were observed.
Water washing of eLP as described above [21] reduces the ammonium acetate content
to minor levels. Incubation of water washed eLP with ammonium salts of fatty acids
(myristate, palmitate, oleate and stearate) led to the formation of the expected fatty acid
adducts as well as the eLP-DeeD adduct (+206 Da). Acylation ofCLP by fatty acids
was markedly slower than acetylation with acetate.
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4.6. Conclusions
On interaction of eLP with DeeD, the expected product eLP-DeeD (7865 Da) is
formed, presumably by formation of the O-acylisourea product at Glu-58 [12]. It is not
the major product, however; these are acetyl-Cl.P (7692 Da) and acetyl-eLP-DeeD
complex (7898 Da). In addition, evidence for a second DeeD adduct is presented, i.e.
CLP-(DCCD)2 (+42Da +206Da +206Da) and the acetylated adduct acetyl-eLP-
(DCCDh (+42Da +206Da +206 Da). The location of the second DCCD has not been
established.
A preliminary kinetic analysis indicates that the primary reaction product is acetyl-CLP
(+42 Da) and not eLP-DeeD (+ 206 Da). Titration of Cys-oa with UQo (Figure.4.9)
has no effect on the DeeD interaction, but elimination of eys-64 as a site of acetylation
and/or trans acylation will require evidence for complete conversion of eLP to CLP-Qo
before addition of DeeD. CID analysis of acetyl-CLP indicates that the probable site
of acetylation is Lys-7 or N-terminal aspartate, an acylation site which in F0 is located
on the M-side of the inner membrane.
The demonstration that the predominant initial reaction is acetylation raises the question
as to whether prior acylation of eLP is required for DeeD addition as opposed to the
direct addition of DCCD to Glu-58 ofCLP. Acylation ofCLP may result in a
conformational change which facilitates the formation of the O-acylisourea product at
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Glu-58, thus providing an explanation for the function of "excess" DeeD [12]. The
product, acetyl-eLP-DeeD, would then be deacylated to give eLP-DeeD. There is
no experimental evidence available to support this view, however, and it is not possible
at present to distinguish between these two possibilities.
The novel observations described above are model reactions with eLP (subunit c) whose
relevance to subunit c function in intact membrane-bound ATP synthase (FIFO ATP
synthase) remains to be established. Nevertheless, they establish possible reactions and
experimental systems using FO inhibitors which were not readily available for
investigation by use of previous analytical methods. Studies of membrane-bound ATP
synthase are now feasible as subunit c and any derivative forms can be extracted by
chloroform/methanol solvent mixtures and then analysed by means ofESIIMS. Of
immediate interest is the question of whether the subunit c-DeeD complex isolated
from mitochondria is or can be acylated in an analogous fashion to acetyl-eLP-DeeD.
Of more general interest is the question of whether acylated forms of subunit c are
normal mitochondrial constituents and whether there is an enzymic acylating system
which operates on the M-side of the mitochondrial inner membrane analogous to the
DeeD-catalysed acylation. It has already been established that normal mitochondrial
subunit c carries an unidentified 42 Da post-translational modification associated with
Lys-43 [21], a possible acylation site which in FO is located on the e-side of the inner
membrane.
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5.1. Introduction
Methane monooxygenases (MMOs) are multicomponent enzyme systems present in
methanotrophic bacteria [1]. These bacteria play an essential role in cycling carbon in
the biosphere by consuming methane produced in anaerobic sediments [2]. The first step
in this process is catalysed by MMO which catalyses the conversion methane to
methanol [1].
MMO ) CH OH + H 0 + NAD+3 2
In addition, MMO has a very wide substrate specificity, that is to say it also catalyses
the oxygenation of a range of organic compounds including alkanes, alkenes, ethers,
alicyclic, aromatic and heterocyclic compounds [1, 3-5]. This broad substrate specificity
justifies the study of the enzyme because of its possible use for the biotreatment of
hydrocarbon pollutants [6]. Detailed structural investigations of MMO have, therefore,
been undertaken in order to understand the mechanism of its enzymatic activity.
Furthermore, an understanding of the biological mechanism may lead to the design of
direct catalysts that could replace the energetically demanding chemical route to
methanol that requires the use of three independent catalysts.
A number of methanotrophs can express a membrane bound particulate (particulate
MMO) or a soluble (soluble MMO) form of the enzyme.
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The particulate enzyme is less well understood although lately progress has recently
been made in its purification and characterisation [7,8]. The soluble enzymes from
Methylococcus capsulatus (Bath) and Methylosinus trichosporium OB3b have been
most studied and reviews of both have appeared recently [9,10]. The soluble MMOs
from these organisms are similar three component systems made up of an hydroxylase, a
reductase and a regulatory protein, B. Electrons from NADH are transferred to the
hydroxylase via the Fe2S2 and FAD cofactors of the reductase. The hydroxylase has two
copies of three subunits in an a2f32Y2 configuration. The Fe-(OH)-Fe site, at which both
O2 and CH4 are activated, resides in the a-subunit. On binding to the hydroxylase,
protein B is believed to cause a conformational change in the former which somehow
regulates electron flow to the diiron site [9].
A 2.2 A resolution X-ray crystallographic investigation of the soluble MMO
hydroxylase from M. capsulatus (Bath) [11] revealed some errors in the published gene
sequence [12]. Therefore a study of the sMMO hydroxylase was undertaken by means
of electrospray ionisation mass spectrometry. This earlier investigation of the sMMO,
performed by A. Buzy [13], revealed that the measured RMMs of the three subunits of
the hydroxylase (a,f3 and y) disagreed with the predicted RMMs, calculated using the
gene sequence as illustrated in Table 5.1.
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Protein subunit Measured molecular Expected Average Measured-
mass (Da) molecular mass (Da) Expected
(Da)
a 60518.3 ± 5.8 60501.3 + 17.0
a' 59 774.9 ± 6.0 59757.5 +17.4
a" 59 973.9 ± 8.4 59956.7 + 17.2
~ 45001.7 ± 2.1 44875.6 + 126.1
Y 19715.6 ± 0.9 19710.5 + 5.1
Table 5.1. The measured and predicted relative molecular masses of the
hydroxylase subunits
The discrepancies in RMM of the a and y subunits were located and identified using a
standard method as shown in Figure 5.1. The first aim of this method is to produce a
low number of cleavage peptides one of which, it is hoped, will retain the discrepancy in
RMM. For this reason a cleavage reagent is chosen which cleaves only at a limited
number of amino acids. Cyanogen bromide (CNBr) is a common choice as it only
cleaves at the C-terminal side of methionine. The next step is to isolate the cleavage
peptide of interest by HPLC before subjecting it to an enzymatic digestion to produce
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much smaller digest peptides (typically ofRMM less than 1500 Da), which are
amenable to MSIMS analysis.
CNBr cleavage (simple mixture)
Isolation of peptide containing discrepancy in RMM by
HPLC
~
Enzymatic digestion of peptide
~
MS/MS analysis
Scheme 5.1. Schematic showing standard method for location and identification
of discrepancy in RMM of protein
a-subunit
The discrepancy of +17 Da for the a-subunit was shown to be present in residues 77-87
by means of the standard method to be present in residues 77-87. MSIMS analysis of
the [M+2HY+ ion of this peptide indicated that residue Leu81 should be replaced by Thr
and Gln82 by Arg (see scheme 5.2).
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a-subunit
CNBr cleavage
~ 10 CNBr cleavage
peptides
aCB3, residues 70-102,
contains the discrepancy
<xCB3isolated
by HPLC
Trypsin digestion
~ 6 tryptic digestion
peptides
aT3,77-87, contains the
discrepancy
aT3 isolat d
by PLC
MSIMS analysis
~ Corrected sequence
Leu81 = Thr -12Da
Gln82 = Arg +28Da
Net +16Da
cherne 5.2. cb matic and re u It of tandard method of location and correction
f r the equeoce error of the a-subunit.
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Furthermore, three proteins ofRMM 60518,59775 and 59974 Da were observed. The
first was assigned as the a-subunit the second and third as the a-subunit having been
cleaved at residues 8 and 6 respectively.
r-subunit
The sequence of the y-subunit was successfully corrected using an method identical to
that used for the a-subunit. The corrections were as follows;
VaI4
His3
IIelLeu
GIn
+14 Da
-9 Da
Net - +5 Da
Figure 5.1. Sequence corrections made for the hydroxylase y-subunit.
p-subunit
Using the standard method the discrepancy of +126.1 Da present in the p-subunit was
located in a tryptic peptide consisting of residues 141-146. MSIMS analysis of the
[M+Hr ion of the 141-146 peptide, performed on the "Quattro II" instrument, indicated
a sequence of the type DEASCNR (predicted sequence TSSCNR) which would have
fully accounted for the anomaly in RMM. Subsequent studies revealed, however, that
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the CID spectrum contained ions of the products of two digest peptides of closely
similar mass, that consisting of residues 141-146, rnlz 792.4, and that of residues 91-96,
rnlz 794.4.
The transmission and subsequent CID of the two peptides was due to the resolution of
Ql being lowered to compensate for the low sensitivity of the experiment achieved by
using the standard method. A revised method was therefore devised which would
increase the sensitivity of the experiment, this consisted of omitting the first two step of
the standard method (Scheme 5.3.). It was recognised that a tryptic digestion of the
~-subunit would produce a complex digestion mixture (46 predicted digest peptides).
The prior data concerning the location of the mass discrepancy would however greatly
simplify the identification of the relevant peptide in the complex digest mixture.
Tryptic digest of intact B-subunit
(Complex mixture)
MS/MS analysis
Scheme 5.3. Revised method for location and identification of discrepancy in
RMM of tbe bydroxylase ~-subunit.
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5.2. Experimental
Purification of the hydroxylase
Growth of the Micapsulatus (Bath) organism was as previously described [14]. The
following modifications of the published procedures for the purification of the
hydroxylase were employed. After the initial ion exchange step, the hydroxylase was
applied to a Superdex 200 gel filtration column. Final purification was via elution of
pure hydroxylase from a Mono Q column using a 0-30% gradient of 1M NaCI. Prior to
injection into the mass spectrometer, buffer was removed from all protein solutions on a
fast desalt column.
Hydroxylase subunit separation
The subunits of the hydroxylase were separated by fast-protein liquid chromatography
(FP-LC) using a Pro-RPC 151l column. The gradient ran from H20 to 90% CH3CH
containing 0.1% TFA. The p-subunit was eluted in approximately 60% CH3CN
containing 0.1% TFA.
Mass Spectrometry
The majority of mass spectra were recorded by means of a "Quattro If' QhQ tandem
mass spectrometer (Micromass UK Ltd, Altrincham, UK) equipped with an atmospheric
pressure ionisation source operated in the nebulizer-assisted electrospray mode. The
potential of the electrospray needle was set at 3.5 kV and the extraction cone voltage
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was varied linearly from 30V at mlz 600 to 90V at mlz 2600. The source temperature
was held at 60°C. The carrier solvent used was a 1:1 mixture of CH3CNIHzO containing
0.1% HCOOH. The samples were infused using a syringe pump (Harvard model II,
South Natic, USA) at a flow rate of 5JlL/min. Calibration was carried out using a
solution of horse heart myoglobin or sodium iodide. Mass spectra were acquired over
the range mlz 600-2000 (mlz 200-2000 for digest spectra) during a lOs scan and by
operating the data system in the multichannel acquisition (MCA) mode.
For low energy MSIMS experiments, precursor ions were selected by Q and a potential
1
difference of 30 V between Q and the hexapole collision cell produced collision
1
energies of 30z eV where z is the number of charges on the precursor ion. The indicated
argon collision gas pressure was 3.2 x 10-3 mbar and Q
2
was scanned over the range mlz
50-900 to produce the product ion spectrum. The Q was calibrated using a mixture of
2
NaI (2Jlg/JlI) dissolved in a solution of water/propan-z-ol (1: 1).All data were processed
by means of the MassLynx data system. The reconstructed mass spectra were obtained
by using the "Max Entropy" algorithm.
Several spectra were acquired on the "Q-ToF" mass spectrometer (Micromass UK,
Altrincham, Cheshire) in which ions produced in an ESI source are transported (in MS
mode) by quadrupole and hexapole ion guides to an orthogonal time of flight (TOF)
mass analyser. In MSIMS mode the quadrupole mass analyser is used to select
precursor ions which are fragmented in the hexapole collision cell to produce fragment
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ions which are analysed by the TOF mass analyser. This instrument has a sensitivity
two orders of magnitude greater than that of the "Quattro II" at a mass resolving power
of approximately 5000, thereby increasing the reliability of sequencing a small number
of tryptic peptides.
Tryptic digestion
Approximately lnmol of the p-subunit in 60% CH3CN containing 0.1% TFA was taken
to near dryness by ultrafiltration in a micron 10 kDa microconcentrator (Amicon Inc.,
Beverley, MA, USA). The protein was reconstituted in 100 J.lL of H20 to which was
added 10 J.lL of CH3CN, 10 J.lL of 1M NH4HC03 and 1150 (w/w trypsin/protein) of
trypsin. The digestion was allowed to proceed at 37°C for 8 h. The digestion mixture
was diluted to approximately 2 pm/ul, in CH3CNIH20 (1:1) plus 0.1% HCOOH before
analysis by ESIJMS and MSIMS.
Reduction and carboxyamidomethylation of the intact p-subunit
10 J.lLof 1 M NH4HC03, 5 J.lLof 100 mM DTT and 5 J.lL of 200 mM iodoacetamide
were added to approximately 1 nmol of p-subunit (dissolved in 60% CH3CN plus 0.1%
TFA) and incubated at 37°C for 30 min. The mixture was then taken to near dryness by
ultrafiltration in a micron 10 kDa microconcentrator and washed twice with 100 J.lLof
0.1% HCOOH. The reduction and carboxyamidomethylation of the protein was
confirmed by ESIJMS with the remainder of the peptide being subjected to a tryptic
digestion as described above.
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5.3 Results and discussion
5.3 (a) Hydroxylase
Figure 5.2. shows the ESI spectrum of the sMMO hydroxylase. Under the low pH
conditions of the spraying solvent the non-covalently bound subunits of the hydroxylase
show individual charge state distributions due to each subunit. Two charge state
distributions of multiply charged ions which corresponds to proteins ofRMM 19714.9
± 1.2 and 45001.4 ± 2.0 are clearly visible.
These proteins are attributed to the 'Y and P subunits respectively. A third charge state
distribution is present at higher mlz values at much lower intensity. Maximum entropy
deconvolution of the ESI spectrum of the sMMO hydroxylase produces a much simpler
spectrum which clearly identifies the three expected subunits. The "MaxEnt" spectrum
of the sMMO is shown in Figure 5.3. This spectrum has been processed so that the
heights of the peaks are proportional to the concentrations of the components.
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986.7
1038.6
1154.8
1251.11409.3
1552.8
897.1
Figure 5.2. ESI spectrum of the sMMO hydroxylase.
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%
19714.7
y-subunit
Y""
45001.1 Hx2 H
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p-subunit
Y""
ex-subunit
59971.5
45034.0
~5045.5
Figure 5.3. "MaxEnt" deconvoluted mass spectrum of the sMMO hydroxylase
132
Chapter 5: Characterisation Of The sMMO Hydroxylase p-Subunit
The a-subunit is of much lower intensity than the other two which is unexpected as the
subunit are known to be in a 1:1:1 ratio.
5.3 (b) p-subunit
In order to study the p-subunit the components of the hydroxylase were separated by fast
protein liquid chromatography. The ESI spectrum of the p-subunit is shown in Figure
5.4.
The spectrum shows a single charge state distribution with charges ranging from +23 to
+65. The "MaxEnt" spectrum, inset, indicates that the measured RMM of the p-subunit
to be 45001.9 Da ±1.9 Da.
~30 ~28
/
I 1 ~26l P2L4 l
O~I~I"~~~~~~~~~~~~~l~~~wz
1400 1600 1800 2000
~48100
pS6
_~44
100 45001.9
~S8
rra
pso,
P40
~S4
44000 4f 000 45600 40000
%
800 1000 1200
Figure 5.4. ESI spectrum of the p-subunits, inset shows the "MaxEnt"
deconvoluted mass spectrum.
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This disagrees with the predicted RMM, calculated from the gene sequence, of 44875.6
Da, by +126.3 Da. In order to locate the discrepancy within the protein, whilst retaining
adequate sensitivity, a tryptic digest of the ~-subunit was undertaken. Prior knowledge
of the primary sequence allows the expected tryptic digest peptides to be calculated in
advance. In this instance a complete tryptic digestion of the ~-subunit should produce
46 digest peptides.
5.3 (c) Tryptic digestion of the p-subunit
Figure 5.5. shows the ESI spectrum of the tryptic digest of the intact ~-subunit.
The notation of the type Tn indicates the tryptic digest peptide. The good agreement
between measured and expected RMM values allowed the majority of the peptides to be
assigned as ~-subunit digest peptides as shown in table 5.2. The tryptic peptides T44 and
T41 were not located in the digest mixture, but were present as part of larger digest
peptides (T44-45, and T40-41) due to incomplete digestion.
Several other digest peptides comprising of a single arginine residue were undetected.
Overall the tryptic digestion of the native ~-subunit confirmed 90% of the primary
sequence.
Only two peptides, of more than four residues, were undetected in the digestion mixture.
Neither peptide T35 nor T21 (RMM 2611.7 and 666.3 Da respectively) were detected at
their expected mJz values. A peptide was, however, detected at 792.4 Da, confirming
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that the discrepancy, now measured more precisely as 126.1 Da, is located in the T21
peptide (residues 141-146 TSSCNR).
10 79S.4
100 671.5 T21 Digest
Peptide
% -, 796.4
%
391.2
1232.8
1241.4
971.5
500 1000 1500
Figure 5.5. ESI spectrum of the tryptic digestion of the ~-subunit, inset shows an
expanded region of the ESI spectrum which contains the T21 tryptic
peptide [M+Ht ion.
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Table 5.2. Tryptic digest map of the ~-subunit
Digest Peptide Residues Predicted RMM Measured RMM Difference
(Da) (Da) (Da)
TI 1-6 691.3 691.4 +0.1
T2 7-7 174.1 Not detected -
T3 8-8 174.1 Not detected -
T4 9-21 1356.7 1356.8 +0.1
T5 22-33 1237.6 1237.6 0.0
T6 34-41 969.5 969.5 0.0
T7 42-43 332.2 332.2 0.0
T8 44-44 174.1 Not detected -
T9 45-74 3412.7 3413.1 +0.4
TlO 75-90 1842.8 1843.4 +0.5
Til 91-96 794.4 794.4 0.0
TI2 97-98 311.2 Not detected -
TI3 99-102 499.2 Not detected -
T14 103-103 174.1 Not detected -
Tl5 104-110 899.5 899.5 0.0
TI6 111-112 261.1 Not detected -
TI7 113-117 689.3 689.5 +0.2
TI8 118-121 553.3 553.3 0.0
Tl9 122-133 1353.7 1353.7 0.0
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T20 134-140 874.4 874.5 +0.1
T21 141-146 666.3 792.4 +126.1
T22 147-167 2448.7 2447.8 0.0
T23 168-175 889.5 889.5 0.0
T24 176-185 1168.6 1168.7 +0.1
T25 186-196 1328.7 1328.9 +0.2
T26 197-201 534.3 534.3 0.0
T27 202-214 1358.7 1358.7 0.0
T28 215-224 1195.5 1195.6 +0.1
T29 225-227 332.2 332.2 +0.0
T30 228-260 3831.2 3831.0 -0.2
T31 261-261 174.1 Not detected -
T32 262-266 725.4 725.3 -0.1
T33 267-270 455.3 455.3 0.0
T34 271-291 2463.8 2463.6 -0.2
T35 292-313 2611.7 Not detected -
T36 314-317 505.3 505.2 -0.1
T37 318-322 604.3 604.3 0.0
T38 323-332 1168.7 1168.7 0.0
T39 333-340 927.5 927.5 0.0
T40 341-348 801.4 801.4 0.0
T41 349-357 1080.5 Not detected -
T42 358-369 1466.7 1466.8 +0.1
T43 370-373 521.3 521.2 -0.1
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T44 374-376 360.1 Not detected -
T45 377-381 601.3 601.3 0.0
T46 382-388 670.4 670.5 +0.1
Table 5.2. Tryptic digest peptide map of the ~-subunit continued
5.3 (d) MS/MS analysis of the T21 trytplc digest peptide of the p-suhunit
Without further separation this peptide was submitted for MSIMS analysis. Figure 5.6.
shows the product ion spectrum of the [M+Ht ion of the T21 peptide acquired on the
"Quattro II"mass spectrometer.
The spectrum shown in Figure 5.6. indicates a radical departure from the predicted
product ions of the T21 peptide (predicted sequence TSSCNR). The peak at mlz 175.1
is clearly identified as ay." fragment ion of a tryptic peptide containing arginine at its
C-terminus. The peaks at mlz 548.9 and 677.9 could be assigned as Y4" and s:'
fragment ions indicating the presence ofD and E at the N-terminus (predicted mlz
values for the Ys" and Y6" ions are 549.3 and 678.4 respectively), further supported by
the presence of the complementary b, ion at mlz 245.1.
The intense low mlz immonium ions at 120.0 and 86.1 are evidence of F and IlLbeing
present in the peptide. The peak at mlz 391.8 may therefore be identified as the b, ion
arising from the sequence DEF fragment and by mass balance, Asp (N) is suggested as
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the missing residue. A tentative assignment of the sequence of the 792.4 Da peptide is
therefore either DEFLIINR or DEFNLIIR. The ultimate sensitivity of the MSIMS
experiment on the "Quattro II" instrument was limited by the fact that lowering the
resolution too much would permit the transmission of the TIl (residues 91-96) tryptic
peptide ofRMM 792.4 mJz.
793.2
10
b2
245.0
F y"l
% 120.0 175.1
IlL
86.1
b3
391.8
y"5
677.9
Figure 5.6. MSIMS spectrum of the MH+ion of the 792.4 mJz peptide acquired on
the "Quattro II" instrument
For this reason the [M+Ht ion of the 792.4 mJz T21 peptide was also submitted for
MSIMS analysis on the "Q-ToF" instrument as it was hoped that the increased
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sensitivity and thus mass accuracy would provide a unambiguous assignment of the
revised sequence.
Figure 5.7. shows the MSIMS spectrum given by the [M+Ht ion of the 792.4 Da tryptic
peptide T21 acquired on the "Q-ToF" instrument. The improved mass accuracy
confirms the assignment made using the "Quattro II"data. The peaks at mlz 505.2 and
402.2 are identified as b, and Y2" ions of the sequence DEFLIIXR. Calculation of mass
difference and the presence of a peak at m/z 289.2, attributed to a Y2" ion, allows the
presence ofN (Asparagine) to be confirmed (156+ 114+ 17+2 Da), giving a final
sequence ofDEFUINR. It is not possible to differentiate between leucine or isoleucine
in a low energy MSIMS spectrum.
93.5
y"4
549.4
100
b2
y"t 245.1
175.1
b3
392.2
y"5
678.5
%
272.2
F
120
100 200
Figure 5.7. MSIl\IS spectrum oftbe MII+ ion oftbe 792.4 mJz peptide acquired on
the "Q-Tor" instrument
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Figure 5.8. y" and b fragment ions produced by the MS/MS experiment on the
(l\I+Ht ion of the T21 tryptic digest peptide.
5.3 (e) Reduction and carboxyamidomethylation of the p-subunit
In order to support further the revised sequence of the T21 peptide a study of the
cysteine residues in the p-subunit was undertaken. Gene sequencing predicts the
presence of two cysteine residues in the p-subunit, one at position 144 and the other at
position 301. The cysteine residues should be present in tryptic peptides T21 and T35.
Clearly if the cysteine residue could be shown not to be present in the T21 peptide this
would support the revised sequence for this peptide which does not include a cysteine
residue.
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Figure 5.9. "MaxEnt" mass spectrum of the reduced and
carboxyamidomethylated p-subunit
Figure 5.9. shows the "MaxEnt" deconvoluted mass spectrum ofthe reduced and
carboxyamidomethylated p-subunit. For each of the cysteines reduced and
carboxyamidomethylated (carboxyamidomethylated cysteine = CsHsN202S) an increase
of 57.l Da (average value 57.1 Da, mono isotopic value 57.02 Da) would be recorded.
The measured RMM is 45059.0 Da ± 1.9 Da, which represents an increase of 57.1 Da
over the measured RMM for the native p-subunit. This result suggests that there is only
one cysteine residue present in the p-subunit, not two (at positions 144 and 301) as
predicted by gene sequencing. In order to locate the single cysteine residue in either the
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T21 or T35 digest peptide the reduced and carboxyamidomethylated p-subunit was
subj ected to a tryptic digestion.
T21
100 peptide 79.4
"- 796.4
% 757.5 793·4 /
Native Digest
890.5
875.5
100 T21 79 .4
After reduction and
carboxyamidomethylationpep~e
-, 796.4
% 757.5 793{1/
890.5
875.5
Figure 5.10. ESI spectra of a selected mJz range of the tryptic digest
before and after reduction and carboxyamidomethylation.
The spectra of the tryptic digest of the native and reduced and carboxyamidomethylated
p-subunit in Figure 5.10. illustrates that there is no change in the MW ion of the 792.4
rnIz ion upon reduction and carboxyamidomethylation. This result confirms that there is
no cysteine residue present in the T21 tryptic peptide, supporting the revised sequence of
DEFLIINR.
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Figure 5.11. ESI spectra ofa selected mJz range ofthe tryptic digest of the 13-
subunit before and after reduction and carboxyamidomethylation.
Conformation that the only cysteine residue present in the J3-subunit was located in
tryptic peptide T35 (position 301) was not possible from the digestion of the native 13-
subunit as this peptide was missing from the peptide map. Figure 5.11 shows that after
reduction and carboxyamidomethylation and then a tryptic digestion a doubly charged
ion of rnJz 1334.60 appears which corresponds to the carboxyamidomethylation of one
cysteine residue in the T35 digest peptide (T35 + carboxyamidomethylated cysteine
RMM = 2667.12 Da, MH2+ 1334.57 mlz).
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Figure 5.12. MS/MS spectrum of the 1334.6-1336.1 mJz cluster of isotope peaks
from the reduced and carboxyamidomethylated tryptic digestion of
the p-subunit.
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MSIMS analysis, shown in Figure 5.12., of the 1334.6-1336.1 m1z cluster of isotope
peaks, undertaken on the "Q-ToF" instrument, produced a partial product ion spectrum
that was consistent with that expected of the T35 peptide containing a
carboxyamidomethylated cysteine. Thus the one cysteine present in the f3-subunit is
located in the T35 digest peptide and not in the T21 peptide which carries the sequence
error.
B = Carboxyamidomethylated cysteine
Figure 5.13. v" fragment ions produced by the MS/MS experiment of the T35
tryptic digest peptide after reduction and carboxyamidomethylation.
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5.4 Conclusions
ESI-MS analysis showed that the measured RMM of the p-subunit disagreed with the
value calculated on the basis on the gene sequence. A tryptic digest of the native p-
subunit was performed in order to locate the discrepancy of 126.1 Da. The digest
confirmed the majority of the primary sequence (90%). The digest peptide T21
(residues 141-146) was identified as the location of the +126.1 Da. MSIMS analysis of
the MH+ ion of the T21 peptide suggested a revised sequence ofDEFLIINR for the
peptide which fully accounts for the difference in mass. Protein and peptide database
searches ruled out the possibility that the 792.4 Da peptide was a product of auto-
proteolysis of the bovine pancreatic trypsin reagent used.
Reduction and carboxyamidomethylation of the subunit confirmed that there was only
one cysteine in the protein (as opposed to the two predicted by gene sequencing), and
that this was present in the T35 peptide and not in the T21 peptide. The tryptic digest of
the reduced and alkylated p-subunit con finned 95% of the primary sequence.
Further support for the revised sequence comes from the fact that the DNA nucleotide
sequence, which originally suggested the amino acid sequence to be TSSCNR, (1), has
to be changed only very little to give rise to the two possible revised sequences,
DEFLNR (2) and DEFINR (3):
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(l) T s s c N R
ACGAGTTC ATC GAACCGG
t t t
{2} D E F L N R
G A C GAG T T C C T GAACCGG
{3} D E F I N R
G ACGAGTTC ATC AACCGG
in which the codes have been displaced slightly to emphasise the similarity. The two
possible revised sequences therefore can arise from a single base change indicated by the
arrows and account satisfactorily for the error in mass of the b-subunit and each is
consistent with all the available evidence.
This chapter describes how the use of ESVMS correctly identified and corrected errors
arising from a slight mis-reading of gene-sequence data to which attention was first
drawn by an X-ray analysis of the protein. Sensitivity problems associated with the use
of conventional CNBr cleavage followed by separation by HPLC and tryptic digestion
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of any peptide of interest were largely overcome by the use of a tryptic digest of the
whole protein followed by the use of CID to analyse the appropriate tryptic peptide
without chromatographic separation although the use of the more sensitive "Q-ToF"
instrument was required to obtain the complete sequence unequivocally.
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6.1 Introduction
Animals can produce specialised proteins called antibodies in response to the presence
of particular antigens (a substance that the immune system regards as foreign or
potentially dangerous) and render it harmless. The precise region of an antigen to which
an antibody binds to is called an epitope. Epitopes can be classified as being either
linear or non-linear. Linear epitopes are composed of a continuous chain of amino acid
residues, whilst non-linear epitopes are made up of two or more short chains of amino
acid residues which are not directly linked but are topographically localised by the
antigen's tertiary structure.
The basic structural unit of an antibody molecule consists of four polypeptide chains,
two identical light (L) chains and two identical heavy (H) chains. The four chains are
held together by a combination of non-covalent and covalent (disufide) bonds. The
molecule is composed of two halves, each with the same epitope binding site, and both
L and H chains usually co-operate to form the antigen-binding surface.
Each heavy and light chain has a variable amino acid residue region (VL & VH)'
Analysis of the amino acid sequence of VL and VH has shown regions of hypervaribility.
Three such regions are present in each heavy and light chains. It is these areas of
hypervaribility that form the precise epitope-binding site of the antibody molecule. As
the epitope-binding site is complementary to the structure of the epitope, the
hypervariable regions are also called complementarily determining regions (CDRs).
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The CDRs form what is called the paratope of the antibody, which binds to the epitope
of the antigen.
The mechanisms of action of neutralising antibodies that bind to viruses which enter the
body are complex and diverse [1,2].
E pitope binding site
Heavy chain (H)
Hinge
Figure 6.1. Basic structure of an antibody molecule
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In vitro there are three classes of anti-human immunodeficiency virus type 1 (HIV -1)
antibody action: (I) inhibition of virus attachment to target cell CD4 receptors [3-6]; (II)
inhibition of the viral genome and associated proteins into the cell interior [4,7] and (III)
inhibition of a subsequent event beyond entry [4,7,8] which has not yet been defined.
Human immunodeficiency virus type 1 (HIV -1) [9] is the causative agent of acquired
immunodeficiency syndrome (AIDS). To date, HIV-I infects 30 million people world
wide, an estimate that has exceeded predictions of its rate of spread (UN World AIDS
Day report; 26th Nov. 1997). The most cost effective strategy to deal with this global
epidemic is the production of a vaccine that will stimulate an effective cellular and
antibody immune response. Present approaches, utilising antibodies, have failed to
consistently stimulate antibodies that are effective against diverse primary strains of
HIV-I [10] although examples of antibodies with high neutralisation efficiency have
been isolated (bI2 [11], 2GI2 [12] and 2FS[13]).
Many different methods have been used in the investigation of'paratope-epitope
interactions. X-ray crystallography and NMR of FAB-virus or FAB-peptide antigen
crystals ( a FAB fragment is a product of an enzymatic digest of an antibody) have
provided detailed structural information in several cases, although both are very time
consuming and require a large amount of sample.
Alternative methods include solid-phase immunoassay where an anti-body specific for
the protein of interest is attached to a polymermic support. Upon addition of the sample
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antigen a complex between the two is formed. A second antibody specific for a different
site of the antigen is then added. The second antibody carries a radioactive or
fluorescent label so that it can be detected with high sensitivity. The amount of second
anti-body is proportional to the antigen in the sample. The sensitivity of the assay can
be greatly increased if the second antibody is attached to an enzyme, such as alkaline
phosphatase. This enzyme can rapidly convert many molecules of an added colourless
substrate into coloured products. Such an assay is termed an enzyme-linked
immunsorbent assay (ELISA).
An alternative method is the use of mass spectrometry. In 1990, Suckau et al [14 ]
combined immunoassay and 2S2CF plasma desorption mass spectrometry to identify
epitopes to the antibody h453. They compared the enzymatic digest patterns of the free
antigen with those obtained when the anitgen was complexed with the antibody. This
method took advantage of the fact that, when complexed, the antigen was protected from
digestion by the antibody and would thus produce a different digest pattern from those
obtained from the free antigen.
This approach to epitope identification, sometimes referred to as epitope excision, has
the advantage of being suitable for the determination of both linear and non-linear
epitopes. Papac et al [15] used a similar method of determining the epitope to an
immobilised antobombesin antibody but utilised matrix assisted laser desorption
ionisation (MALDI)-MS. Parker et al [16] have also employed the epitope excision
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approach to determine an epitope on the HIV IIIB Gag protein again using MALDI-MS
as have the majority of subsequent studies of this type.
An alternative method of epitope identification is the epitope extraction approach. This
involves the pre-digestion of the antigen before reaction with the antibody. Those digest
peptides that contain the epitope are selectively bound by the antibody, leaving the non-
epitope peptides to be removed. Zhao et at [17] have identified a linear epitope in the
peptide melitten using this strategy. Jeyarajah et at [18] have demonstrated that the
bound epitope containing peptides need not be eluted from the immobilised antibody
prior to MALDI -MS analysis. Whilst Madit et al [19] have shown that either epitope
excision or extraction may be performed without immobilising the antibody. In these
experiments separation of the bound and unbound peptides was performed by means of
ultrafiltration. Lyubarskaya et al [20 ] have employed affinity capillary electrophoresis
with electrospray ionisation mass spectrometry for the screening of digest peptides
containing epitopes.
In a recent study Lu et al [21] have demonstrated the identification of protein antigens
in complex mixtures with a magnetic bead monoclonal antibody.
In the majority of the MALDI-MS studies performed so far the antibody has had to be
immobilised before being incubated with the complete or digested antigens. The non-
epitope peptides then have to be washed away, before the epitope-angtigen complex can
submitted for mass spectrometric analysis. Both of these steps increase the complexity
of the process and the time required for the analysis.
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Another disadvantage ofthese types of analyses is that as the antibody is covalently
bound to the solid matrix, only the non-covantly bound peptides are desorbed during the
MALOI process. The actual complex between the antibody and the epitope is not
observed by mass spectrometry. This can increase the possibility of mis-interpretation
of non-specific interactions between the antibody and those digest peptides of the
antigen that do not contain the epitope.
The work detailed in this chapter is concerned with the binding activities of a micro-
anitbody (Micro-Ab). The Micro-Ab is a 17 amino acid cyclised peptide derived from
the third heavy chain COR of a murine monoclonal antibody (MAb) IgG 1, called F58
[22]. MAb F58 neutralises several T-cell lab-adapted (TeLA) and primary strains of
HIV -I. The Micro-Ab was shown previously to neutralise five TeLA strains of HIV-l
[8,13] and act by inhibiting an event beyond the fusion of HIV-I with its target cell
membrane.
MAb F58 binds to a region on the glycoprotein (gp) spikes present on the surface of the
HIV-Ilipid envelope membrane [23-24]. There are about 70 spikes on the surface of
each viron [25]. The spikes consist ofa transmembrane glycoprotein gp41 molecule,
interacting non-covalently with a glycoprotein gp120 molecule, to form an oligometric
structure which recent data proposes is a trimer [26,27,28]. Gpl20 houses the e04
primary cell receptor binding site (or C04-binding site) [29]. It is believed that Gpl20
and gp41 are involved in the complex interactions between HIV -1 and its target cell, that
result in HIV·I genome entry into the cell interior.
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Matrix protein
Viral core
(includinz viral zenome)
Figu re 6.2. Schematic representation of HIV-l
Gp120 is highly glycosylated and composed of regions demonstrating degrees of
sequence variability between different strains of HfV-I. In one monomeric gpI20
molecule there are five conserved regions (Cl-CS) and five variable regions (VI-VS).
Neutralisation epitopes in gpI20 have been mainly identified in the CD4 binding site,
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V3 and V2 regions. It is to the third variable region (V3) that MAb F58 specifically
binds.
At the tip ofthe V3 region, the minimum epitope for F58 binding is IxxGPGR as
determined by ELISA studies. The strongest binding, however, was seen with a peptide
representing the amino acid sequence RKSIRQRGPGRA. Previous studies have shown
that Micro-Ab competes with MAb F58 for binding to V3 peptides representing this
region and suggest the Micro-Ab binds to this region of gp120.
A: CDLIYYDYEEDYYFDYC
B: RKSISIGPGRAFF ATGD
C:CTRPNNNTRKSIHIGPGRAFYATGEIIGDIRQAHC
I I
Figure 6.3. Amino acid sequences of; A: Micro-Ab; B:V3 Z-321 peptide; C:V3
BRA peptide
160
Chapter 6: Epitope-Paratope Interactions Between HIV-I And A 17Amino Acid Micro-Antibody
N
==Z I..o...
I
Ctlo
o
u
).. • 0 I
161
Chapter 6: Epitope-Paratope Interactions Between HIV-1 And A 17Amino Acid Micro-Antibody
6.2. Experimental
Sample preparation
Lyophilised micro-antibody, HIV-I Z-321 V3 peptide (MRC-ADP; ARP 765) and HIV-
1 BRA V3 peptide (MRC-ADP; EVA 7026) were separately dissolved in 50 mM
ammonium acetate at lrng/ml.,
Micro-Ab and V3 peptide binding
The Micro-Ab and V3 peptides, present in equimolar quantities, were incubated at 37°C
for 1 hour.
Proteolytic digestion and digest peptide binding
Z-321 or BRA peptide and chymotrypsinltryspin in the ratio 1:50 were dissolved in
50mM ammonium acetate. For partial digestion of the V3 peptides the digestion
mixture was incubated at 4°C for 2 minutes; for complete digestion of the V3 peptides
the digestion mixture was incubated for 1 hour at 37°C. The digest reagent was removed
by ultrafiltration using a Microcon microconcentrator (Ami con, INC. Beverley MA).
The V3 digest peptides were either diluted to working concentrations in
acetonitrile/water plus 0.1% formic acid for ESIIMS analysis, or incubated with the
Micro-Ab (1:1 ratio) for 1 hour at 37°C to allow any binding to occur. Digest peptide
mixtures or digest peptide incubated with the Micro-Ab were then submitted directly for
ESI-MS analysis.
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Mass Spectrometry
All experiments were performed in a "Quattro II" tandem mass spectrometer of QhQ
configuration equipped with electrospray ionisation. Instrumental conditions were as
described in chapter 3. Micro-Ab and V3 peptides were dissolved in CH3CNIH20 plus
0.1% HCOOH at a concentration of approximately 3pmlilL Calibration was performed
using the multiply charged ions of horse heart myoglobin or the monoisotopic ions of
NaI.O
6.3. Results and discussion
6.3 (a) Relative molecular mass determination
Figure 6.5. shows the ESI spectrum of the Micro-Ab sprayed in a solvent consisting of a
1:1mixture of H20/CH3CN plus 0.1% HCOOH. Peaks due to a singly and a doubly
charged ion corresponding to a peptide of measured monoisotopic RMM 2291.7 Da ±
0.2 Da are present. This compares well with the calculated value of 2291.8 Da for the
Micro-Ab, confirming both its primary sequence and the presence of one disulfide bon»
in the peptide. Na" adducts are also present in the spectrum.
The ESI spectrum of the HIV-l V3 Z-321 peptide is shown in Figure 6.6. The spectrum
shows peaks assigned as singly, doubly and triply charged ions corresponding to a
peptide of monoisotopic RMM 1778.9 Da ± 0.08 Da, this is in exact agreement with the
calculated RMM and therefore confirms the primary sequence of the V3 Z-321 peptide.
The ESI spectrum of the larger HIV-l V3 BRA peptide is shown in Figure 6.7. The
spectrum shows a series of peaks corresponding to ions of the charge states 2+ to 6+.
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The measured average RMM of the V3 BRA peptide is 3866.5 Da ± 0.4 Da. Again this
compares very well with the calculated RMM of the peptide of 3866.4 Da and confirms
the primary sequence of the HIV -1 V3 BRA peptide and the presence of one disulfide
bond. An unidentified peptide ofRMM 3780 Da is also present.
RMM = 2291.7 Da ± 0.2 Da
100
%
Figure 6.5. ESI spectrum of the Micro-Ab
The measured RMMs for the Micro-Ab and the V3 Z-321 and BRA peptides were in
good agreement with their expected values and therefore confirm their primary
sequences. The presence of a disulfide bond in both the Micro-Ab and the BRA peptide
is confirmed as, in each case, the RMM would be 2 Da lower without the bond.
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RMM = 1778.9 Da ± 0.08 Da
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Figure 6.6. ESI spectrum of the HIV-l V3 Z-32l peptide
%
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RMM = 3866.5 Da ± 0.4 Da
Figure 6.7. ESI spectrum ofthe HIV-l V3 BRA peptide.
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6.3 (b) Incubation of the Micro-Ab with the V3peptides
To determine whether or not they interacted, the Micro-Ab and the V3 peptides were
incubated using the conditions that resulted in 95% loss of infectivity of HIV-I strain.
The ESI spectrum of the Micro-Ab incubated with the V3 Z-321 peptide is shown in
03+ 02+
l A+o~~·I~~~I"~I.~~~~--~--~--~I..~~I--~nVz
SOO 1000 lSOO 2000 2500
Figure 6.8.
100-
%
A=Micro-Ab
B =Z-321 V3
D =Complex of
the Micro-Ab plus Z-321
Figure 6.S. ESI spectrum of the Micro-Ab incubated with the V3 Z-321 peptide at
eqimolar concentrations for 1 hour.
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The spectrum shows the typical contributions of the Micro-Ab (labelled A) and the V3
Z-321 peptide (labelled B). A third series of peaks is also present (labelled D) these are
assigned as a doubly and a triply charged ion. These ions correspond to a protein of
4072.7 Da; this value compares well with the expected average RMM of a complex
between the Micro-Ab and the V3 Z-321 peptide of 4073.4 Da. This result indicates
that the complex formed between the Micro-Ab and the V3 Z-321 peptide in solution by
a non-covalent interaction can be maintained and detected in the gas phase.
The above procedure was repeated with the Micro-Ab and the V3 BRA peptide. Figure
6.9. shows the spectrum of the products of the incubation of the Micro-Ab and the V3
BRA peptide.
Again the spectrum shows the typical contributions of the Micro-Ab (labelled A) and the
V3 BRA peptide (labelled C). An additional series of peaks are also present, labelled E,
these are assigned as triply and quadruply charged ions, which correspond to a protein of
average RMM 6159.1 Da. This compares favourably with the expected RMM of a
complex between the Micro-Ab and the V3 BRA peptide. These results, as for the
Micro-Ab and the V3 Z-321, suggest that the interaction between the Micro-Ab and the
V3 BRA peptide can be preserved by ESI and thus detected directly by mass
spectrometry.
The results of the relative molecular mass determination and incubation studies suggest
that the Iow RMM of the Micro-Ab makes it more amenable to ESI-MS studies than an
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investigation using a standard antibody (typical RMM approximately 150 kDa). The
observation that the non-covalent interaction between the Micro-Ab and the V3 peptides
can be maintained by electrospray ionisation and thus detected directly by mass
spectrometry means the immobilisation of the antibody and the subsequent washing
procedures characterised by the majority of the previous mass spectrometric analysis
found in the literature can be omitted.
100-
%
Figure 6.9. ESI spectrum of the Micro-Ab incubated with the V3 BRA peptide
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6.3 (c) Epitope identification
As outlined in the introduction at the beginning of the chapter two main methods for
epitope identification exist; epitope excision where the antibody-antigen complex is
formed and then subjected to digestion, or the epitope extraction method where the
antigen is predigested and the digest peptides (only some of which contain the epitope)
are incubated with the antibody.
In order to use the epitope excision method it was considered necessary to separate the
unbound Micro-Ab and V3 peptide from the Micro-Ab-V3 complex in solution so that
the digestion pattern of the bound and free antigen could be compared.
Previous efforts to use the epitope excision method without separating the free Micro-
Ab and respective V3 peptide from the bound complex indicted that the digestion
patterns were difficult to assign unambiguously. All attempts to perform this separation
by HPLC and FPLC were unsuccessful. The epitope extraction method was therefore
employed, where the antigen would be predigested before being incubated with the
Micro-Ab (Scheme 6.1.).
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V3 peptide
Eptope -
Step 1:Trypsinl Chymotrypsin~-
digest of V3 peptides
Step 2: Incubation ofV3 digest
peptides with the Micro-Ab
Micro-Ab
Step 3:Immunoprecipitation of
epitope containing digest
peptides with the Micro-Ab
1 Step 4: Detection of epitopepeptides bound to Micro-Ab
ESI-MS analysis
Scheme 6.1. Schematic representation of the epitope identification experiment
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The ESI spectrum of the chymotryptic digestion of the Z-321 V3 peptide is shown in
Figure 6.10.
10 (1-12l+
(I-I0f+
(1-12)3+
1-13)3
%
(14-17f (1-10 +
Figure 6.10. ESI spectrum of the products ora chymotryptic digest of the V3 Z-321
peptide
Using the "Biolynx" protein/peptide database the predicted products of a chymotryptic
digestion of the V3 Z-321 peptide were obtained. The good agreement between the
measured and predicted RMM values allowed the majority of the peaks present in the
spectrum to be assigned as chymotryptic digest ions of the V3 Z-321 peptide.
The major digestion products were found to be the digest peptides consisting of the 1-
10, 1-12 and 1-13 amino acid residues. All the chymotryptic digest peptides produced
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are listed in table 6.1. The next step in the procedure was to incubate the digest pep tides
with the Micro-Ab for immunoprecipitation of the epitope containing digest peptides to
occur.
Z-321 peptide Charge State Expected RMM Measured Difference
Fragment (Da) RMM(Da) (Da)
1-10 2+ 535.8 535.8 0.0
1-12 2+ 644.9 644.9 0.0
1-12 3+ 430.2 430.2 0.0
1-13 2+ 718.4 718.5 0.1
1-13 3+ 479.3 479.3 0.0
14-17 1+ 363.2 363.3 0.1
Table 6.1. Expected and measured RMM values of the chymotryptic digest
products of the V3 Z-321 peptide
The ESI spectrum of the chymotryptic digest products of the Z-321 peptide incubated
with the Micro-Ab is shown in Figure 6.11. As in Figure 6.10. the most abundant peaks
are assigned as ions corresponding to the expected digest peptides of the V3 Z-321
peptide. Also present are peaks assigned as the characteristic singly and doubly charged
ions of the Micro-Ab.
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(MicroAb + 1-12i+
(1-12)2+
(1-10)2+
(1-12)3+
100
(MicroAb + 1-131+
{2MicroAb} + I-lOr
({2MicroAb} + 1-12)3+
e.Mi~b} + 1-13)3
(1-13)2+ % Micro-Ab+1-10)
(1_13)3+
(14-17) +-, ~Micro-Ab )2+
Micro-Ab+
Figure 6.11. ESI spectrum of the cbymotryptic digest products of the Z-321 peptide
incubated with the Micro-Ab. Inset shows expanded mJz range.
The inset of Figure 6.11. shows an expanded view of the mlz range 1650-2050. The
peaks contained within this range were assigned as ions corresponding to the Micro-Ab
binding to the digest peptide consisting of amino acid residues 1-10, the digest peptide
consisting of amino acid residues 1-12 and the digest peptide consisting of amino acid
residues 1-13. Peaks corresponding to two Micro-Abs binding to the digest peptides
consisting of amino acid residues 1-10, 1-12 and 1-13 were also present.
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No binding of the Micro-Ab to the digest peptide consisting of amino acid residues 14-
17 was observed, despite its presence in the digest peptide mixture. These data suggest
that amino acid residues 14-17 are not required for binding of the V3 Z-321 peptide to
the Micro-Ab, and that the epitope is to be found in amino acid residues 1-10.
No non-specific interactions between the Micro-Ab and other digest peptides present in
the digestion mixture were observed. The digestion and binding data are summarised in
Figure 6.12.
Additional information on the epitope, now believed to be contained in amino acid
residues 1-10, was sought by subjecting the V3 Z-321 peptide to a tryptic digestion.
Trypsin digests on the C-tenninal side of arginine and lysine residues and so was
expected to produce either/or both of the peptides containing amino acid residues 2-10
and 3-10. A partial and complete tryptic digestion of the Z-31 was performed to
produce both the peptides consisting of the 1-10 and the 2-10/3-10 amino acid residues
to confirm the results obtained with the chymotryptic digestion of the V3 Z-321 peptide
in one experiment.
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1 10 17
RKSISIGPGRAFF ATGD
1-10
1-12
1-13
14-17
Figure 6.12. Major peptides produced by a chymotryptic digestion of the V3 Z-321
peptide. The green lines represent peptides that were bound by the
Micro-Ab, the red line represents the peptide that was not bound by
the Micro-Ab.
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100
%
(1-10)3+
(1-10)2+
(ll-17t
Figure 6.13. ESI spectrum of the products of a partial tryptic digestion of the
. V3 Z-321 peptide
The partial tryptic digest of the V3 Z-321 peptide produced the digest peptides
consisting of amino acid residues 1-10 and 11·17 and a small amount of that consisting
of the 3-10 amino acid residues as assigned in Figure 6.13. and illustrated in Table 6.2.
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Z-321 peptide Charge state Expected Measured Difference
fragment RMM(Da) RMM (Da) (Da)
1-2 1+ 303.2 303.1 0.1
1-10 1+ 1070.6 1070.6 0.0
1-10 2+ 535.6 536.0 0.2
1-10 3+ 357.6 357.6 0.0
3-10 1+ 786.5 786.5 0.0
3-10 2+ 393.7 393.8 0.1
11-17 1+ 728.3 728.4 0.1
Table 6.2. Expected and measured RMM values for the products of a partial
tryptic digest of the V3 Z-321 peptide
Figure 6.14 shows the ESI spectrum of the products of the partial tryptic digestion of the
Z-321 peptide incubated with the Micro-Ab. The spectrum contains peaks which
correspond to the expected digest peptides and the Micro-Ab. The inset of the spectrum
shows two peaks which correspond to doubly and triply charged ions assigned as being
due to the Micro-Ab binding to the digest peptide consisting of amino acid residues I-
10. No binding of the Micro-Ab to the peptide containing amino acid residues 11-17
was detected.
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(l1-l7r (MicroAb + 1-10)2+
/
(1-10)2+ (MicroAb + 1-10)3+
Figure 6.14. ESI spectrum of the products of a partial tryptic digest of the
V3 Z-321 peptide incubated with the Micro-Ab
The Z-321 peptide was then subjected to a complete tryptic digestion the products of
which are shown in Figure 6.15. As expected the most prominent peaks are due to the
digest peptides containing amino acid residues 1-2,3-10 and 11-17. The peptide
containing amino acid residues 2-10 (cleavage after the arginine residue at position 1)
was not produced. The products of the complete tryptic digestion of the Z-321 peptide
were incubated with the Micro-Ab to determine what, if any, effect on binding to the
Micro-Ab removing the RI{ dipeptide would have.
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Figure 6.15. ESI spectrum of the products of a complete tryptic digestion of the
V3 Z-321 peptide
Figure 6.16. shows the ESI spectrum of the incubation of the products of the complete
tryptic digestion with the Micro-Ab.
The spectrum shows peaks corresponding to the digest peptides assigned previously and
peaks corresponding to singly and doubly charged ions of the Micro-Ab. No binding,
however, was observed between the Micro-Ab and any of the digest peptides produced
by the complete tryptic digestion of the V3 Z-321. These data suggests that that peptide
1-2 (arginine-lysine) is an essential part of the Micro-Ab epitope (ie RKSISIGPGR)
although it did not bind itself to the Micro-Ab.
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The data from the incubation of the products of partial and complete digestions of the
V3 Z-321 peptide incubated with the Micro-Ab are summarised in Figure 6.17.
%
(11-17)+
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(1-2t
( (5-10t
(3-10)+
"
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Figure 6.16. ESI spectrum of the incubation of the products of a complete tryptic
digestion of the V3 Z-321 peptide incubated with the Micro-Ab
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Complete tryptic digestion
11-17
3-10
1-2
• •
RKSISIGPGRAFF ATGD
1-10
11-17
Partial tryptic digestion
Figure 6.17. Major peptides produced by a partial and complete tryptic digestion
of the V3 Z-321 peptide. The green line represent the peptide that
was bound by the Micro-Ab, the red lines represent the peptides
that were not bound by the Micro-Ab.
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This result was supported by the results ofa complete tryptic digest of the V3 BRA
peptide. The ESI spectrum of the products of a tryptic digest of the V3 BRA peptide is
shown in Figure 6.18.
No attempt to reduce and alkylate the disufide bridge in the V3 BRA peptide was made
(as the epitope is removed from the terminal cysteine residues) so some of the predicted
digest peptides are missing from the digest mixture.
A digest peptide was identified as being the peptide containing amino acid residues 10-
18, (sequence; KSIHIGPGR). As trypsin cleaves after arginine and lysine residues this
digest peptide is an unexpected tryptic digest product.
The major digest peptides produced by the trypsin digestion of the V3 BRA are listed in
table 6.3. The 11-18 digest peptide omitted both the R and K residues i.e. SIHIGPGR,
which were found to be necessary for binding between the Micro-Ab and the V3 Z-321
peptide, whilst the 10-18 peptide included just the K residue on the peptide i.e.
KSIHIGPGR.
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Figure 6.18. ESI spectrum of the products of a tryptic digestion of the V3 BRA
peptide
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BRA peptide Charge state Measured Expected Difference
fragment RMM(Da) RMM(Da) (Da)
19-31 1+ 1425.8 1425.7 0.1
19-31 2+ 713.4 713.7 0.3
11-18 1+ 836.5 836.5 0.0
11-18 2+ 418.9 418.8 0.1
21-31 1+ 1207.7 1207.6 0.1
21-31 2+ 604.7 604.5 0.2
-1-9,32-35- 2+ 765.7 765.8 0.1
-1-9,32-35- 3+ 510.8 510.9 0.1
22-31 1+ 1044.5 1044.5 0.0
22-31 2+ 523.0 522.8 0.2
10-18 1+ 964.7 964.6 0.1
10-18 2+ 483.0 482.8 0.2
10-18 3+ 322.7 322.7 0.0
Table 6.3. Expected and measured RMM values of the products of a tryptic
digestion of the V3 BRA peptide.
Figure 6.19. shows the ESI spectrum of the products of a tryptic digestion of the V3
BRA peptide incubated with the Micro-Ab.
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Figure 6.19. The ESI spectrum of the products ora tryptic digestion of the BRA
peptide incubated with the Micro-Ab. Inset shows expanded m/z
range.
The spectrum shows peaks corresponding to the digest ions as assigned previously and
those due to the singly and doubly charged ions of the Micro-Ab. The inset shows peaks
assigned as one and two Micro-Abs binding to the digest peptide containing amino acid
residues 10-18. No binding to the digest peptide containing amino acid residues 11-8 is
observed. This result suggests that the 11-18 peptide, sequence SIHIGPGR, is unable to
bind but the addition of the K residue, i.e. the 10-18 peptide, is able to bind. This
supports the view that both the R and K residues, or in the case of the BRA peptide just
the K residue is required in addition to the SIHIGPGR sequence for binding to the
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Micro-Ab to take place. The relatively small amount of binding observed betweeb the
KSIHIGPGR peptide and the Micro-AB could be due to the presence of just the lysine
residue as opposed to the presence of both the lysine and arginine residues as in the
binding between the Micro-Ab and the Z-321 peptide.
6.4. C8029 Ne2ative Micro-Ab bindin2 studies
The C8029 peptide (Negative Micro-Ab) lacks one tyrosine residue from position 5 or 6
of the Micro-Ab. This peptide, in contrast to the Micro-Ab, has no activity against
HIV-l. An ESI-MS study of its binding to the two HIV-l V3 peptide was therefore
undertaken to determine if the absence of the tyrosine residue would effect the binding
to the V3 peptides.
10
%
1000 1200 1400 1600 1800 2000 2200 2400 26&Yz
Figure 6.20. ESI spectrum oftbe C8029 peptide (negative Micro-Ab)
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The measured RMM of the negative Micro-Ab of2129.6 Da ±0.2 Da compares well
with the calculated RMM of the peptide of2129.8 Da (Figure 6.20). This confirms the
primary sequence of the peptide and the presence of one disufide bond as in the standard
Micro-Ab. The negative Micro-Ab was then incubated with the V3 peptides in a manner
identical to that used for the standard Micro-Ab and the V3 peptides. Figure 6.21.
shows the spectrum resulting from the incubation of the negative Micro-Ab with the V3
Z-321 peptide. It shows the typical negative Micro-Ab contributions and those due to
the Z-321 peptide. The inset shows an expanded mJz range which shows peaks
corresponding to triply and quadruply charged ions of a complex between the negative
Micro-Ab and the V3 Z-321 peptide. This result suggests that binding between the
negative Micro-Ab and the V3 Z-31 peptide can take place despite the absence of the
tyrosine residue.
100
%
B3+
C2+
10
A: C8029
B: V3 Z-321
C: C8029 + Z-321
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Figure 6.21. Negative Micro-Ab incubated with the V3 Z-321 peptide.
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Upon incubation between the negative Micro-Ab and the V3 BRA peptide peaks
corresponding to a complex between the two were also observed (spectrum not shown).
The ESI spectrum of the C8029 negative Micro-Ab incubated with the products ofa
partial tryptic digestion of the V3 Z-321 peptide are shown in Figure 6.22. The inset
shows peaks corresponding to the Negative Micro-Ab binding to the peptide containing
amino acid residues 1-10 of the V3 peptide. This result indicates that the negative
Micro-Ab binds in a manner identical to that of the standard Micro-Ab although, as
stated previously the negative Micro-Ab shows no activity against HIV -1. Incubation of
the negative Micro-Ab with the products ofa complete tryptic digestion of the V3 Z-321
peptide indicates that no binding occurs to the peptide containing amino acid residues 3-
10 as was found for the standard Micro-Ab (Figure 6.23.).
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Figure 6.22. ESI spectrum of tbe C8029 negative Micro-Ab incubated witb tbe
products of a partial tryptic digestion of tbe V3 Z-321 peptide
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Figure 6.23. ESI spectrum of tbe negative Micro-Ab incubated witb tbe products of
a complete tryptic digestion of tbe V3 Z-321 peptide
6.5. Conclusions
The results presented in this chapter indicate that the low RMM value of the Micro-Ab,
as compared to the high RMM ofa typical antibody of approximately 150 kDa makes
possible the investigation of its binding activity to two RIV -1 V3 peptides by means of
ESI-MS analysis on a quadrupole instrument of geometry QhQ equipped with
electrospray ionisation.
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RMM determinations of the Micro-Ab and the V3 peptides Z-321 and BRA were within
0.1% of their calculated values. Furthermore it has been demonstrated that ESI can
produce gas phase ions which correspond to a non-covalent complex between the Micro-
Ab with the V3 peptides and can thus be detected by MS. The interaction between the
Micro-Ab and the V3 peptides implies that its antiviral activity is mediated by binding
directly to the virus particle. The ability to maintain and detect the complex between the
Micro-Ab and the V3 peptides negates the need to immobilise the antibody and perform
several washing procedures which characterise the majority of the MALDI-TOF-MS
studies previously performed.
Partial and complete enzymatic digests of the V3 peptides produced peptides which
were subsequently incubated with the Micro-Ab. The Micro-Ab selectively bound only
to the peptides containing the epitope. Results indicted that the consensus epitope was
RKXXXGPGRA. The dipeptide R and K was found to be required for binding to take
place, although a smaller amount of binding was observed with just the K residue at the
C-terminus end of the epitope in the case of the BRA peptide. Experiments to determine
the epitope were completed in under two hours.
The negative Micro-Ab (lacking one tyrosine residue of the standard Micro-Ab) was
also observed to bind to the V3 peptides. Incubation of the negative Micro-Ab with
partial and complete digestion of the V3 peptide indicated that it binds in an identical
manner to the standard Micro-Ab.
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